The industry which we goanna discuss today is Hospital. Yes! that capex heavy and not an everyday trending industry. As it is going to be very long post, I wish you take out a separate time from your day to read this, bookmark this if you don’t have time 45 minutes currently at least. But don’t skim read it. Trust me it will be fun like reading some good book.

So, without a delay here we go:

But let’s first see how top hospital stocks performed in last 5 years.

If you have invested in any of them and held it, you would have made a decent amount of money with right position sizing!

So, then it’s stupid to invest now in this, they already had their bull run phase now valuations must be high & growth would slow down due to their bigger size.

(I don’t know if you thought that, but that was exactly my perspective few months ago and...)

That is very wrong judgement!!

(To study this, we have to keep our biases aside irrespective it’s positive or negative.)

For this will go from basic, but I assume this that you are bit familiar with industries key metric like ARPOB, ALOS etc.

Finally, let’s start cooking…

Bed Can’t Be Built in a Hurry

Picture a bank opening a new branch or a coffee chain opening a new outlet. Rent a space, fit it out, hire a small staff and within a few months you’re open for business. If demand shows up, supply follows quickly.

A hospital doesn’t work that way.

And this isn’t really a comparison of construction timelines. A large hotel or office tower can take just as long to build as a hospital. The difference is what happens after the building is ready.

A new bank branch is useful from day one, the moment the first customer walks in.

A new hospital wing is not.

It first needs government medical licensing that can take months on its own. Then comes the installation and calibration of highly specialized medical equipment. And finally - the hardest part of all - it needs doctors who are actually willing to work there.

Not just any doctors.

Senior specialists who have spent a decade or more building expertise, reputations and patient relationships don’t relocate for a new building the way a bank teller might transfer to another branch.

That makes hospital capacity fundamentally different from almost every other physical business. Sounds similar to hotel building, let’s check it out how it is even different from that.

There is a second difference and it’s just as important.

A hospital can never even try to run ‘fully booked’ the way a hotel chases 100% occupancy.

If every bed is occupied, there’s nowhere to put the next accident victim. Or the next heart attack. Or the next emergency surgery.

So, hospitals deliberately stop admitting new patients long before every bed is filled. Yes, you read it right!

The practical ceiling is usually around 70% occupancy.

Cross that line too often and the system begins to break down.

• Doctors become overstretched.

• Waiting times increase.

• Care quality starts to deteriorate.

Ironically, a hospital that’s ‘too full’ is often operating less effectively than one with spare capacity.

That brings us to the puzzle at the heart of India’s hospital industry.

For years, hospital chains increased profits without adding many new beds at all.

Instead, they became progressively better at utilizing the beds they already owned, pushing occupancy closer and closer to that 70% ceiling.

Eventually, however, that strategy stopped working.

Not because demand disappeared.

Not because people suddenly became healthier.

But because hospitals simply ran out of room to squeeze more out of existing capacity.

And that’s where the real story begins.

Once the occupancy ceiling is reached, every hospital chain faces the same question:

How do you create the next bed?

The answer isn’t as straightforward as constructing another building.

In fact, there are four very different ways to expand hospital capacity.
(The below chart will describe the key differences in them!)

Acquisition - Buying Time

Imagine opening a hospital tomorrow morning without waiting 2-3 years for construction to finish.

That’s essentially what an acquisition allows.

Instead of buying land, pouring concrete, obtaining dozens of approvals and waiting years for patients to discover a new hospital, an operator simply buys one that’s already running. The doctors are already there. Patients already trust the brand. Referral networks have been built over decades. Cash begins flowing almost immediately.

What you’re really buying isn’t a building.

You’re buying time.

That distinction mattered enormously after COVID. Hundreds of standalone hospitals emerged from the pandemic financially exhausted despite serving healthy patient demand. For the first time in years, large hospital chains had the opportunity to purchase functioning hospitals rather than build them. It was a rare window where capital could replace patience.

But acquisitions solve one problem only to introduce another.

Hospitals aren’t factories. You can’t bolt one onto another and expect everything to work. Doctors need convincing. Clinical protocols need standardizing. IT systems must be integrated. Hospital culture - something patients never see but employees feel every day has to become one.

That’s why acquisitions are often won or lost long after the deal is announced.

Buying a hospital is easy.

Making it feel like it has always belonged to your network is the difficult part.

Greenfield - Building from Scratch

Every great hospital began as an empty plot.

Greenfield expansion is the purest form of growth because nothing exists on day one. The land has to be acquired. The building has to be designed. Operating theatres, ICUs and diagnostic equipment must all be installed before the first patient ever walks through the door.

Even then, construction is only half the journey.

A hospital without doctors is just an expensive building.

The real work begins after the ribbon-cutting ceremony. Specialists need to establish their practice. Local physicians must trust the new facility enough to refer patients. Insurance companies need relationships. Patients need confidence that the new hospital is capable of treating their families.

None of that happens overnight.

This is why greenfield expansion tests something more valuable than capital.

It tests patience.

For several years, the balance sheet carries the burden while the income statement slowly catches up. Investors often mistake this period for underperformance. In reality, it’s simply the unavoidable cost of creating an entirely new healthcare ecosystem.

Yet if management gets the location right, recruits the right clinicians, and waits long enough, greenfield hospitals often become the most valuable assets in the network.

The longest road can also produce the biggest rewards.

Brownfield - Close to a Free Lunch

If greenfield is about creating a hospital, brownfield is about unlocking one.

Instead of starting from scratch, management asks a much simpler question:

“What more can this hospital become?”

Perhaps there’s an unused floor waiting to become patient rooms. Maybe another operating theatre can be added. Perhaps the ICU can be expanded or an adjacent block converted into additional capacity.

Almost everything that makes a hospital difficult to build has already been solved.

Patients know the hospital.

Doctors have established thriving practices.

Referral networks are functioning.

The pharmacy, laboratories, parking, and support infrastructure are already there.

Adding another hundred beds isn’t like opening another hospital.

It’s more like widening an already busy highway.

That explains why brownfield economics look so different. According to Aster DM’s management, a brownfield bed typically costs ₹0.8–1.1 crore, compared with ₹1.5 crore or more for a greenfield bed. More importantly, those beds begin earning their keep far sooner because they inherit an ecosystem that already works.

The numbers tell the story. After expanding its Kannur hospital through a brownfield project, Aster’s EBITDA margin improved from 18.5% to 22.5%. No breakthrough technology. No dramatic change in demand. Just better utilization of infrastructure that already existed.

But the problem in this one is that the remaining space remains limited and once filled you can’t do much of it.

Asset Light - Selling Without Owning

Not every hospital chain wants to own every hospital.

Some have realized their greatest asset isn’t the building.

It’s knowing how to run one.

The Operations & Management model flips the traditional equation. Another party owns the land, funds construction and carries the balance sheet risk. The hospital operator contributes what is arguably harder to replicate - clinical expertise, operating systems, brand, quality standards and day-to-day management in exchange for a fee.

It’s the healthcare equivalent of a luxury hotel chain.

Marriott doesn’t need to own every hotel carrying its name.

Its expertise is valuable enough on its own.

The economics are compelling. Very little capital is tied up in bricks and mortar, allowing operators to expand far more quickly than traditional ownership models would permit.

Of course, the trade-off is equally obvious.

If you don’t own the asset, you don’t capture all of its economics either.

Asset light models exchange long-term ownership for capital efficiency. They are less about maximizing returns from a single hospital and more about expanding a network without stretching the balance sheet.

For the right operator, that’s an exceptionally attractive bargain.

So, you must have a question in your mind now, which one is best after all this?

To get what’s actually in the article, subscribe and get it for free.

Trust me, it would be fun for any investor or finance enthusiast!

Before you begin reading, a small note…

…

As with any investment thesis, there is a possibility that some assumptions prove wrong, execution falls short or future developments change the outlook entirely. I encourage you to challenge every argument made here, verify the numbers yourself and arrive at your own independent conclusions.

…

Investments involve high risk. Do your own research and consult a financial advisor before investing.

This is our first time analyzing what we have published so far with a positive outlook on the businesses, results of them have come out a month ago, so good time to analyse it now after settling of dust. I will try to keep a performance track each on 6 months’ time interval. How good or bad do you feel the idea is, tell me in the comments.

Since February this year, out of 5 stocks (excluding Samhi) till now we have discussed not much has happened in many of them, the prices were flattish to slightly up, 1 big outperformer drive the whole portfolio returns of the newsletter.

If we go to numbers straight, the newsletter had the alpha of 1.8% over BSE Small Cap 250 Index, if we put each at equal weightage. Though that’s very different from my actual portfolio with 11.93% alpha in the same period, it is much due to position sizing and some stocks which got doubled and one got 50% up in the same period which are yet to be covered in the newsletter.

Yatharth Hospital & Trauma Care

Research

It was my first article on any stock with positive outlook on business and pushing and encouraging the business as undervalued compared to its potential of earnings in medium future.

The thesis is playing perfectly as expected Q4 was their highest ever revenue and profitable quarter. The outlook by management is that they are expecting more growth than this year which had 40% revenue growth YoY with margin improvement upcoming.

The cash flow issue (the govt scheme receivable) is getting sorted as they are going 100% private in their new acquired hospitals and guiding from 35% govt payor to 25% payor mix from govt. in next 2 financial years.

You can check it out in their concall Q4 FY25-26

Canara Robeco AMC

Research

As I said earlier market sees it as:

One business, one revenue stream, one product category. That’s it!

That’s true in the respect that it is the current profile of the business, but future gives them optionally to move into many more spaces with better margin business.

This article explains it well on this front: Futuristic Look on Canara Robeco AMC

Now but coming to this quarter, numbers are bit worrisome because they have lost a tiny percentage of market share in the equity segment despite being equity focused when compared to their diversified peers gaining the market share. But despite this, the stock did not stumble much, it is hovering at 250 per share from month even after the result.

Showcasing that the downside is protected and upside potential is phenomenal even if nothing happens or no thesis plays out, in a bull market 25-30% YoY growth this AMC is not going to be left anytime soon. Being Equity heavy gives them edge on this side.

In short, I am still bullish on this though in short term it may bleed some opportunity cost.

Poly Medicure

Research

Poly Medicure is the biggest when we talk from market capitalization perspective across all 5. Its recent quarter showed the real management talk by growing its revenue by 21% YoY showcasing the reality in the mgmt. emphasizing demand is coming back though some headwinds exist. On the margin front, I think they have done exceedingly well full year wise. In this quarter specially the margins are bit at stress due to their raw material price increase, acquisitions impact etc.

Now on thesis front, it is intact quite well. I don’t have major thing to add on so yes that’s it on this for now.

Gravita India

Research

Gravita is very new when we talk about our newsletter stock, as I explained in this article Going One Step Deeper on Gravita India.

The company is currently going through a capex phase, and its benefit will be reaped from the next Q1 as their one plant goes live and revenue starts coming from Q2 majorly. Though market will not wait for Q2 if the mgmt. executes on their words.

Nothing major to check or see as we have already analyzed the Q4 results and after that nothing major has happened into the picture. So, let’s wait for the hero to come in the movie to see how it unfolds.

Dodla Dairy

Research

Dodla Dairy is the one which I am not really sure about, I saw the problem of their pricing power issue early on before writing but was not that keen that how big it is, as it seems it is way more than I expected the whole industry decides the price not a single company can and will be able to do. And on VAP front, it can be margin accelerative but not the growth. And I see there are many better business models valued at slightly above the value but are worth more than this kind of investment.

So, I would look out one to two quarter to actually access the model better and then would give my better views though as of now, I am not very bullish on the stock.

Summary Insights

To put it better my current portfolio does not seem antifragile rather it is a steady business capable of withstanding heavy tides without being swept away. Many more business are coming and on Dodla, it will also decide on that factor if we get better risk reward than this. You can actually see that though our first priority is quality, but the other main considering factor is downside protection and large upside.

As Mohnish Pabrai said:

With this, I would like to end the article.

Part 2 is where we get into the real work - the financials, the margin story, global expansion logic, valuation, risks and what FY27–FY29 could actually look like.

Index

1. Return Ratios

2. Margin Sustainability

3. The Expansion Blueprint

4. Financial Health Check

5. Valuation

6. Final Framing

Return Ratios

Here is a number that almost never shows up in Gravita bull cases:

ROCE in December 2022 was 31%. By mid-2025, it had declined to approximately 13%.

That is a 50% reduction in return on capital employed over roughly three years. For a company whose entire investment thesis is built around being a “compounding machine,” this deserves a proper explanation.

Let me give it one.

The QIP Effect

In FY25, Gravita raised ₹1,000 crore through a QIP - one of the largest capital raises in the company’s history, oversubscribed 3.5 times. Of that, ₹772 crore went toward debt repayment, working capital, and general corporate purposes. The balance sat temporarily invested at the time of the H1 FY26 filing.

When you raise ₹1,000 crore in equity and park a significant portion of it in treasury instruments while the business absorbs it, your denominator (capital employed) expands immediately. Your numerator (EBIT) does not catch up until the capital is deployed into productive assets. The result is a mathematical compression of ROCE that looks alarming on a chart but is entirely mechanical in nature.

This is not an excuse. It is context. The question worth asking is: at what ROCE will this capital eventually be deployed?

Management has been explicit the 25% ROIC benchmark is non-negotiable for any new capital deployment. In Q2 FY26, despite the expanded capital base, the company reported a ROIC of exactly 25% on operational capital - meaning the working capital cycle, existing plant efficiencies, and VAP mix improvements are generating returns in line with the stated benchmark.

Two things are visible in this table.

First, the “peak” years of FY22–FY23 were exceptional because Gravita was running its lead business at high utilization with minimal new capital requirements. The scrap procurement network was built, the customers were locked in, the VAP mix was improving, and the balance sheet needed no fresh equity. In that environment, incremental capital requirements are low and returns look extraordinary. They were but they were also a product of that specific phase of the business cycle.

Second, every year since FY24 has seen the operational ROIC hold steady at 25%+. The business has not become worse at allocating capital. It has simply been given more capital than it can productively deploy in one or two quarters. That is a different problem - and a much more solvable one.

Why ROE Will Re-Expand From Here

ROE = Net Profit Margin × Asset Turnover × Financial Leverage

Gravita’s path to higher ROE is not through leverage (they are deliberately conservative on debt). It is through the numerator expanding faster than the denominator as QIP capital gets deployed into productive assets.

The copper plant at Mandvi (₹160 crore capex), the Phagi lead capacity expansion (40,500 MTPA added in May 2026), and the ongoing aluminium and rubber scale-up are all absorbing QIP proceeds now. As these assets generate return over FY27–28, the numerator catches up to the expanded capital base and ROE normalizes back toward the 28% range.

This is not a hope. It is the arithmetic of what happens when ₹1,000 crore of QIP capital moves from treasury into 25%+ ROIC assets over an 2-3 year deployment cycle.

Margin Sustainability

Let me show you something striking about Gravita’s EBITDA margin over seven years:

This table is telling you something fundamental about how Gravita’s economics work.

The margin has roughly doubled from FY19 to FY26 - not because commodity prices doubled. The margin expanded because the structural composition of the business changed. Every year, a slightly larger share of revenue came from value added products, from verticals with better unit economics and from sourcing channels with better scrap discounts.

So now can this trajectory continue or are we approaching a structural ceiling?

The Input Cost Structure - Why Margins Are Defensible

In a typical manufacturing business, raw material cost represents 60–70% of revenue and moves with commodity cycles. When input prices rise, margins compress. When they fall, margins expand. The business is essentially a commodity spread play.

Gravita’s cost structure is different in one crucial way: the raw material is scrap, not primary metal.

Scrap consistently trades at a discount to LME - historically 10–18% for lead scrap, 8–15% for aluminium scrap, 12–20% for copper scrap. This discount exists structurally because informal scrap collectors and traders lack the scale and logistics to command LME pricing. When Gravita buys scrap, it is already buying at a built-in discount to the commodity price it will eventually receive when it sells refined metal.

The margin, therefore, is not “selling price minus input cost” in the traditional sense. It is scrap discount + VAP premium + operating efficiency − processing cost. None of those three components moves with LME prices in the short term. That is why Gravita’s margins have been relatively stable even as lead prices oscillated between ₹130–170/kg over the same period.

The VAP Mix - Margin Engine

Value-added products - lead oxide, red lead, refined alloys, specialty battery materials carry meaningfully better margins than pure refined lead. Management’s target is for VAP to exceed 50% of total portfolio, against roughly 46–47% currently.

Each percentage point shift toward VAP carries approximately ₹2-3 crore of annual EBITDA at current scale - not enormous in isolation, but the cumulative effect over three to four years of consistent mix improvement is what has driven the margin from 8.3% to 10.6%.

What is the natural limit to VAP mix?

You cannot sell 100% of your refined lead as specialty oxide the market has absorption limits. But at 50-55% VAP mix (which is the realistic target), there is still 3-8 percentage points of mix improvement available from where we are today. Combined with improving unit economics in copper and aluminium as those verticals scale, an EBITDA margin of 11.5-12.5% by FY29 is achievable without heroic assumptions.

Share Capital Conviction

The Recent Margin Dip

Q4 FY26 saw EBITDA margin contract from 11.78% in Q3 to 9.59% a (219 basis) point sequential decline that spooked the market and caused the stock to drop 2.24% on results day.

Let me explain what actually happened.

Three things converged in Q4: elevated scrap procurement costs as the company built inventory ahead of new capacity commissioning, higher fixed-cost absorption from the Mandvi copper plant pre-revenue phase, and a 69% sequential drop in other income from hedging gains. None of these is structural. Inventory builds reverse. New plants generate revenue. Arbitrage or Hedging income is lumpy by nature.

The full year FY26 EBITDA margin of 10.6% - slightly above FY25’s 10.4% - is the number that matters. The quarterly results were more of a noise than anything else.

Why Non-Lead Growth Actually Expands Margins

Here is something counterintuitive. New verticals - rubber, copper, aluminium are currently running at lower margins than the mature lead business.

Shouldn’t their growth dilute the overall margin?

Not over time, for one structural reason: these verticals have higher EBITDA/ton potential at maturity than lead does today.

Copper recycling at full integration has a guided EBITDA/Ton of ₹65/kg versus lead’s current ₹23/kg. Even at a conservative ₹50/kg in the first two years of ramp up, copper will be a margin accretive vertical the moment its revenue contribution becomes meaningful.

Aluminium, once the MCX ADC12 hedging contract is approved, unlocks the same hedging discipline that made lead so consistent - and aluminium alloys carry better VAP premiums than primary aluminium. That is another vertical that looks margin dilutive today but is margin-accretive by design at maturity. I have not taken the impact in the image of it to being conservative on this side.

The short-term drag from new verticals is real.

The Expansion Blueprint

Management has gone on record with a set of targets that are either impressively ambitious or naively optimistic depending on your prior. Let me lay them out precisely and then assess each one.

The Vision 2029 Commitments:

• 25%+ volume CAGR from FY25 to FY29 (~7 lakh ton annual capacity by FY28)

• 35%+ profitability growth (PAT CAGR)

• 25%+ ROIC maintained throughout

• VAP contribution above 50% of total portfolio

• Non-lead business above 30% of revenue

The Capacity Math

In May 2026, Gravita added 40,500 MTPA of lead capacity at its Phagi (Jaipur) facility taking that plant to 75,819 MTPA. This single expansion, combined with the Mandvi copper greenfield at 29,400 MTPA, adds roughly 70,000 MTPA of nameplate capacity in one quarter.

Current total capacity is in the 4 - 4.5 lakh ton range across all verticals. To reach 7 lakh ton by FY28, the company needs to add roughly 2.5 – 3 lakh tonnes of capacity over two years. That is aggressive but not implausible - particularly if aluminium and copper ramp more quickly than current consensus assumes.

The one honest caveat here is that nameplate capacity and realized volumes are different things. New plants typically run at 50–65% utilization in their first year. The path from 7 LTPA capacity to 7 LTPA production runs through a 12–18 month ramp-up cycle. Volume guidance for FY28 is more accurately a capacity target that becomes a volume reality by FY29. Though market starts pricing this before anything else.

The Geographic Expansion

Gravita currently has operational presence in 10+ countries - Ghana, Tanzania, Senegal, Sri Lanka, and others. The Africa model has worked because Gravita entered markets early and built procurement networks before formal recycling infrastructure developed.

The next geographic frontier and this is strategically the most important initiative underway - is procurement relationships in the US, Australia, and Germany for copper scrap. These are developed markets with established scrap trading ecosystems where Gravita is essentially an unknown new entrant.

Why not in current areas we have discussed about it in Part 1…

If you wish to:

The Lithium Ion, Paper & Steel Optionality

Management has flagged lithium-ion battery recycling, paper recycling and steel recycling as “scaling new growth avenues” alongside the core verticals. These are not yet meaningful contributors to revenue or profit.

Just to clarify they have lithium-ion battery recycling system but the management is understanding the mechanics as of now and it is also in ballpark after FY28-29.

But here is why they matter: each new vertical follows the same playbook.

• Turnkey: Build recycling plants for others, learn the technology, establish customer relationships.

• Investment: Commission own recycling capacity at modest scale using internally accrued capital.

• Integration: Build procurement network, improve scrap sourcing economics, expand VAP mix.

• Maturity: Asset-light network effect, consistent ROIC above 25%.

Gravita has run this playbook in lead (over 30 years), aluminium (10 years), and rubber (3 years). Lithium-ion and steel are in Phase 1 today. The market is not pricing any of this in. That is a feature, not a bug - it means the current valuation does not require these to work out on lithium ion, steel and paper.

That is the case I always see with Mr. Market it is generally efficient in short term and inefficient sometimes by big margins in long term.

Financial Health Check

Gravita has compounded revenue at roughly 25–27% CAGR over the last five years, going from around ₹1,800 crore in FY21 to ₹4,265 crore in FY26. The growth has come from three places simultaneously: volume expansion, value-added product (VAP) mix improvement, and the addition of new verticals.

But revenue in a recycling business is a somewhat misleading number because it moves with metal prices too. The metric that actually matters is EBITDA per Ton because that tells you whether the business is getting better at its craft or just riding a price cycle.

The margin has more than doubled from FY19 to FY26 - not because commodity prices doubled, not because revenues merely doubled (they more than tripled). The margin expanded because the structural composition of the business changed. Every year, a slightly higher share of revenue came from value-added products, from verticals with better unit economics, and from sourcing channels with structurally better scrap discounts.

Two things stand out in the EBITDA/Ton column specifically.

First, the consistent improvement from FY19 to FY25 is not accidental. It is the direct output of the VAP strategy each year, a slightly higher share of revenue comes from refined alloys, lead oxide, red lead and specialty products that carry better margins than pure refined lead. That is the compounding mechanism inside the business model.

Second, FY26 saw a slight dip in EBITDA/Ton it is transitional. The company was running elevated capex, integrating the Romania rubber acquisition, and absorbing the initial fixed costs of the RMIL copper entry simultaneously. Fixed costs ran ahead of incremental revenues. That kind of dip, in that context, is actually a sign of management building for the future rather than protecting near-term numbers. The full-year EBITDA margin of 10.6% above FY25’s 10.4% is the number that matters.

The Balance Sheet

Gravita has maintained a net debt to equity below 0.3x through the entire expansion phase. This kind of thing is very rare to find.

The business generates strong operating cash flows because of the spread model when you don’t own commodity risk, working capital is reasonably predictable. Beyond that, management has a genuine aversion to leverage that shows up consistently in capital allocation decisions. The ₹160 crore Mandvi copper recycling capex was funded from QIP proceeds for example.

A near debt free balance sheet in a capital-intensive manufacturing business is not just a financial metric. It is an optionality store. When the next acquisition or capacity opportunity appears, Gravita can move fast without needing a rights issue or taking on leverage at unfavorable rates. That is a meaningful competitive advantage over every recycling peer that is already stretched.

With a current ratio of 5.27x and a debt-to-equity of just 0.20x as of the latest available filings, Gravita’s balance sheet is cleaner than most Indian mid-cap manufacturers half its size. That quality does not get reflected in any P&L multiple, but it is real and it matters at least to me.

Share Capital Conviction

Valuation

At the current market cap of approximately ₹12,300 Cr.

The trailing P/E of 33x looks expensive in isolation. But trailing multiples are the wrong frame for a company in active investment mode. The more relevant question is: what is the market implying about FY28 - FY29 earnings and is that implication reasonable? (This is what I have learnt from Mr. Shankar Nath over time)

The PEG Ratio

The PEG ratio (Price/Earnings ÷ Earnings Growth Rate) for Gravita currently stands at approximately 1.11x - remarkably reasonable for a business of this quality.

A PEG below 1.0 is conventionally “cheap” Between 1.0 - 1.5, a growth stock is typically considered fairly valued. Above 2.0, you are paying a significant premium for growth that needs to materialize. Though it is a very vague metric to track in this form but the other from which is:

At 1.11x, the market is not pricing in heroic assumptions. It is not paying a massive premium for optionality. It is pricing in approximately 25% earnings CAGR over the next three years (including all other stuff like management quality, earnings quality etc.) which, given the track record of roughly 30% PAT CAGR, is simply asking this business to continue doing what it has already demonstrated it can do.

That is a much more comforting framing than “30x P/E.” I think valuations are justified with this logic.

Final Framing

After all of this the return ratios, the margin structure, the expansion math and a proper valuation - here is the most honest summary I can give you.

Gravita is a high-quality business going through a high complexity & highly changing phase. The ROCE compression is real but mechanical, not structural. The margin dip in Q4 FY26 is temporary, not a trend. The current valuation is pricing in base-case execution, not optionality.

The single most important variable for the next few years is the copper vertical. If copper sourcing scales on timeline and EBITDA/Ton trends toward the ₹55–65/kg range, the earnings inflection in FY28 will be sharp enough to re-rate the stock even if the multiple stays constant. If copper takes longer than expected the stock drifts sideways while the rest of the business quietly compounds underneath.

Then after Copper, it becomes lithium-ion recycling to me though that’s a different topic to cover, we will be covering as time passes by and more clarity comes on it.

Neither outcome is catastrophic. One is much more interesting than the other and other than the other.

Downside is Protected & Upside is the Way…

The monitoring checklist going forward:

• Copper volume in Q1 and Q2 FY27 concalls

• EBITDA margin trajectory - Inflection back toward 11%+

• ROIC 25% is the commitment holding it is the test

• Expansion capacity utilization ramp ups

That is Part 2. If Part 1 gave you the story, Part 2 gives you the framework to stress-test it. What you do with both is yours to decide.

My Other Writings

• Is It the Inflection of SAMHI Hotels

• Not Just a Consumables Company Anymore

• One of the Most Overlooked Sectors - Dairy

• Reopening the File on Canara Robeco AMC

• Reginal Hospital Chain Quietly Scaling in North India

And don’t forget to give your opinion good or bad about the company or myself whatever.

Feel free to blast it out!

Disclaimer: This is not investment advice. It is a research exercise for educational purposes. Numbers referenced are from public filings, concall transcripts and author research. Do your own due diligence. The author may or may not hold position in the stock discussed.

(If this does not excite you to understand the business then saying humbly, please don’t read further because it will get more boring only)

Months ago, I was not keen on the industry itself, I was trying to ignore the sector but somehow it was coming in my screener again & again across all different criteria’s then I thought let’s just read about it no need to hurry on it, and I later found it was actually one of the best industry to play the double engine Megatrend + Megatrend = Super Duper Megatrend.

Index

• Industry Tailwind

• About Company

• Key Metrics to Track

• Business Model

• Business Verticals

• Acquisition of RMIL

• Management Analysis

Industry Tailwind

The market often treats recycling companies like cyclical commodity businesses. But something deeper is happening underneath - the industry is slowly moving from an unorganized, low trust ecosystem toward formal, regulation driven circular economy.

And that shift matters because regulation is not just improving sentiment; it is actively reshaping profit pools.

EVs and Battery Energy Storage Systems (BESS) are extremely metal intensive. EVs use significantly higher copper compared to ICE vehicles, while BESS systems require large quantities of copper, aluminium and lithium-ion batteries for power transmission, current collectors and storage infrastructure. Even lithium-ion batteries themselves internally use copper and aluminium foils.

This creates a second-order effect most investors underestimate:

The world is not just electrifying.
It is becoming structurally dependent on recycled metals.

Why?

Because mining alone cannot economically or environmentally support the future demand curve for copper, aluminium and battery materials.

That is where regulation enters the picture.

EPR (Extended Producer Responsibility)

Every company that sells batteries in India - manufacturers, importers, brand owners is legally required to ensure those batteries are collected and recycled at end of life. Compliance is proved through EPR credits, which only registered recyclers can generate by processing actual battery waste. Producers who fall short of their annual targets face penalties and operational restrictions. This converts recycling from a low-margin scrap business into a regulated compliance service with guaranteed, policy-driven demand.

Battery Waste Management Rules (BMRW)

India’s first dedicated regulatory framework covering all battery types - lithium ion, lead acid, nickel cadmium and many others. All producers, importers, recyclers and bulk consumers must register on a CPCB managed centralized portal; unregistered entities cannot legally trade in battery waste. Annual EPR targets are set to escalate progressively, meaning demand for certified recycling capacity only grows. The rules also force large institutional battery users - EV fleets, telecom firms, industrial operators to channel their scrap exclusively to registered recyclers, cutting off informal players from premium feedstock.

MSTC Exchange Portal

Before this platform, EPR credit trades happened bilaterally and privately, making it easy to suppress prices or fabricate transactions. MSTC a government run exchange, brought credit trading onto a transparent platform where prices are discovered through open competition. This ended the ability to undervalue credits through informal deals and made fraudulent credit generation far more visible to regulators. Compliant recyclers with genuine capacity now receive fair market value for every credit they generate.

CPCB Audits

The Central Pollution Control Board (CPCB) has shifted from passive registration to active physical verification. Audits now involve surprise inspections, cross referencing scrap procurement invoices against reported output, and third-party capacity assessments. The primary target is recyclers who claimed large processing volumes on paper to generate EPR credits without actually processing that volume. Penalties include registration cancellation, credit forfeiture, and criminal referral making the fake credit model no longer worth the risk.

GST Reverse Charge Mechanism

Under RCM, when an organized buyer purchases battery scrap from an unregistered informal supplier, the buyer must pay 18% GST directly to the government out of their own pocket. While the buyer can later claim an input tax credit, the immediate cash burden and compliance paperwork make sourcing from informal suppliers significantly more expensive and administratively painful. This erodes one of the core cost advantages informal recyclers had cheap, off book scrap procurement and discourages organized players from dealing with the unregistered supply chain.

TDS on Battery Scrap

Tax Deducted at Source on scrap purchases means every transaction creates a paper trail reported directly to income tax authorities. Informal sellers who were previously invisible to the tax system suddenly have declared income they cannot explain without filing returns which then exposes their entire operation to scrutiny. For sellers who cannot recover TDS because they don’t file returns, it functions as a permanent cost deduction that makes informal participation economically unviable at scale.

Conclusion: These reforms don’t operate in the isolation they compound. Informal operators squeezed on credit legitimacy, input costs, tax exposure and supply chain access simultaneously cannot survive on margins alone. Organized, compliant, scaled recyclers are the only ones built to absorb all of it and every informal exit is a direct transfer of market share to them.

Just a side note while I could have combined somethings like MSTC Portal & EPR credits at first only but wanted to explain each in different segments so you kind of get essence of each. But they are actually not separate so below image illustrates that beautifully.

About Company

Gravita India was started in 1992 when the recycling market was not very established especially in India where it was not given any importance, so they started the business as metal scarp trading where after 3 years established their own plant in Jaipur and then going International by Sri Lanka in 2000s.

Fast Forward to today, it has its own 39 yards with 2200+ touch points with more scrap collection of more than 3,30,000 Metric Tons (MT).

You know the interesting part they don’t have their own yards currently in America & Australia but in coming years, you will see massive uptake either in more touch points or their own yards. We shall discuss about this in more detail in our Acquisitions part.

Key Metrics to Track:

• Procurement Network: This defines the moat of business. The more the network the better it is, as you can procure at lower prices than anybody else even in hard times like this.

• VAP % of Sales: (Value Added Products) The margin increase of the business depends on this only.

• EBITDA Per Ton: This is the metric which tells efficiency of the business. Keep in mind that the different scrap metal has different EBITDA per ton. It can also be said as ₹/kg (both means same)

• Capacity Expansion: The way to grow in this business is adding capacity as it is in manufacturing business so capacity addition means growth.

Business Model

Most recycling companies operate one way - buy scrap, process it, sell the output.

But but but…. Gravita runs four distinct operating models simultaneously, and understanding the mix is more important than understanding any single one. This one part took me more time to understand than any other part.

The 1st Overseas model, despite being the most profitable at ₹28/kg, is not infinitely scalable as the supply is limited not to mention their demand for these products are also capped. The regulation in Africa is completely different, and it is chaotic to fight for each new plant. Not to mention talented manpower search is also required.

Now the 2nd model foreign sourced scrap processed and sold locally. This is centered around the Mundra facility, which is the volume workhorse handling roughly a third of total throughput but at lower margins of ₹18/kg because it absorbs freight and import costs before the first ton is processed. We can say the margins are very hard to improve from here in this.

The 3rd Institutional procurement model, where Gravita sources directly from Airtel, Vodafone, Luminous and similar large battery users, is structurally the most interesting from a long-term perspective. It currently contributes only 8–10% of volumes, but as EPR enforcement tightens and bulk consumers are legally required to channel their scrap to registered recyclers, this pipeline will grow without Gravita having to compete for it on price. It is margin compressed today at ₹12/kg, but the regulatory framework effectively converts it into a captive supply channel over time.

The tolling model - where Amara Raja and Exide hand over battery scrap and receive refined lead back is the least glamorous on paper but the most capital-efficient. At INR 7–8/kg, margins look thin, but RoCE exceed 25% because Gravita carries no working capital on the scrap itself. It is essentially a processing fee business with blue chip counterparties, which means predictable volumes, zero procurement risk and high returns on the capital deployed.

The real strategic insight here is that Gravita is not dependent on any single sourcing channel or geography. When global scrap prices spike, the tolling and institutional models provide a buffer. When domestic scrap is scarce, the import and overseas models absorb the volume gap. This blended architecture is what allows the company to sustain volume growth across cycles rather than being whipsawed by any one input variable. We can take example from current situation where their growth has slowed down to mid-teens but not completely destroyed which will come back in few quarters.

Business Verticals

• Aluminium is the second vertical, at around 9% of volumes. The process is similar, source aluminium scrap, melt it, produce alloys for die casting and automotive applications. This business is currently running at a fraction of its potential in India, for reason that the MCX approval of ADC12 is still pending where management side work is already and it is on MCX to start the contract which can happen anytime soon hanging from around a year.

• Rubber recycling is newer. Gravita acquired a tyre recycling company in Romania and is commissioning an India plant at Mundra that should be operational in Q1 FY27. The outputs are tyre pyrolysis oil, carbon black and crumb rubber.

Beyond these verticals, Gravita also has a Turnkey Solutions division that designs and builds recycling plants for third parties globally. It has delivered over 70 such projects across countries including Qatar, UAE, Saudi Arabia, Poland and Chile. This generates modest revenue but builds technical credibility and extends geographic relationships.

(You might be wondering what about lithium-ion batteries, so mgmt. acknowledges the fact that it is still on very nascent stage for them, and they are still understanding the business, so it is kind of in their back burner but not of main focus till FY 2028-29 though it’s one of the most interesting part of their business.)

I don’t think you don’t know F&O [Future & Options] and hedging in it for example buying call and put together in different ratios to earn the spread in that it’s basically similar to that.

Why to complicate let’s take a hypothetical example:

Suppose the company buys scrap when copper is ₹800/kg and plans to sell the finished product later. To avoid risk, it locks today’s price on an exchange (MCX). Now, even if copper falls to ₹750 or rises to ₹850, the price movement is offset by the hedge. So, the company doesn’t make or lose money from price changes - it earns mainly from the spread (buying scrap cheaper, say at ₹780, and selling closer to ₹800)

Acquisition of RMIL

Gravita didn’t just buy a copper company - it basically bought a launchpad.

Instead of starting with trading and then figuring things out, they directly entered manufacturing by acquiring RMIL’s integrated Gujarat facility. And right after that, they announced a recycling plant to support it from the backend. That sequencing is very intentional.

RMIL itself is a solid base. It’s been around since 1946, runs a 31,200 MTPA facility, did around ₹1040 crore revenue and ₹82 crore EBITDA in FY26. Currently works at 8% Margin with only 50% utilization.

Now the interesting part is the Mandvi recycling plant.

₹160 crore capex, 29,400 MTPA, fully funded internally. Location is smart - near Gujarat ports, so scrap sourcing with exports both become easier. Instead of buying copper at market prices, Gravita will produce it in-house and feed RMIL.

That’s where the margin jump comes from.

Currently ₹45/kg to management guiding ₹65/kg with integration. That’s not small improvement; that’s a proper structural shift. And at a combined level, they’re targeting 25%+ ROCE.

Only real risk here:
Copper scrap sourcing.

Unlike lead, where they already have a strong global network, copper scrap is concentrated in developed markets US, Europe, Australia. Building that sourcing capability is new for them, and that will decide whether timelines actually play out.

That’ why I told you earlier they are going to expand their presence in these regions.

Share

Management Analysis

Here is the most honest way to think about Gravita’s management - they have spent a decade building credibility in one business and are now betting it on five new ones at the same time. Whether that ends well depends entirely on whether the discipline that defined the lead business travels with them.

They Say 25% ROIC Is a Hard Line. Do The Numbers Back That Up?

Most companies set return thresholds on investor slides and quietly abandon them when growth opportunities show up. Gravita maintained approximately 24% ROIC even through FY26, a year when they were simultaneously running a large capex program, integrating an acquisition and commissioning new plants. That is not an accident that is a management that genuinely screens capital decisions against a return benchmark before committing. The proof of that discipline is actually visible in what they chose not to do - they did not rush into lithium ion or copper at scale before the unit economics were clear. They ran pilots, understood the margin profile, then committed capital.

Leave a comment

The Guidance Game - Under Statement & Over Deliver

Lead prices swung from $1,950 to $2,250 to $2,000 per ton between FY21 and FY25 at LME. Gravita’s EBITDA margins moved in a straight line from 7.2% to 10.4% across the same period regardless of where prices traded. That single data point tells you more about management quality than any concall quote ever could. Margins expanding steadily through a volatile commodity cycle means they are consistently doing what they said they would - improving mix, growing value-added products, tightening operations and none of it is dependent on commodity luck.

But There Is a Thing Worth Noting

The aluminium MCX approval has been described as “any time now” from last year without materializing. Taken alone this is a minor point - it is genuinely a regulatory dependency outside management’s control. When rubber, lithium ion and copper all start having their own “imminent milestones” the same pattern in multiple segments simultaneously becomes a more meaningful signal about execution rather than just regulatory delay.

…

The honest answer of management analysis is that we have surety of past performance but the future growth they are expecting from is not their primary region before. The margins, the ROIC, the debt-free balance sheet, the conservative guidance points to a team that has earned the right to be given the benefit of the doubt. FY27 and FY28 will be the years that either confirm or challenge that view.

THIS IS ONLY PART 1… PART 2 WILL BE THE NEXT!!

He has put together a really insightful piece on how the industry is scaling rapidly. Highly recommend reading the full article!

The Megatrend Investor

Recycling Megatrend

I live in Panipat. A small city, not far from Delhi.Most people know it for the three historic Battles of Panipat. Today, it’s known for something else too.Panipat is one of India’s biggest textile hubs. Bedsheets. Fabrics. Blankets.Just a few lanes away from my house, there’s a scrap dealer. Garbage keeps piling up there, day after day…

Read more

7 months ago · 88 likes · 43 comments · Megatrend Investor

My Other Articles:

Is It the Inflection of SAMHI Hotels

Not Just a Consumables Company Anymore

One of the Most Overlooked Sector - Dairy

Reginal Chain Quietly Scaling in North India

Reopening the File on Canara Robeco AMC

Recommend Me to Others

Share Capital Conviction

So why we are talking about this, now when it has remained such a darling stock, well at that time the story was sold, numbers were weak, valuation was overpowered but now no one seems to talk about that, numbers have improved significantly so does the valuations thanks to this bearish phase of market.

This is going to be a long one. If you are the kind of person who needs an elevator pitch first, here it is:

SAMHI is not bad; it is just boring. The market wanted a story stock. What it got is a slow-compounding real estate with brand business that will likely earn its way back to respect over the next 24 to 36 months.

Just a one more thing to add that we are not covering the financials and valuation of the company in this article, we will do it according to the response of you…

So now without further ado, Let’s get started…

Disclaimer: This article is for educational purposes only and does not constitute investment advice. Please do your own research or consult a financial advisor before making any investment decisions.

About Hotel Industry

Hotel Industry is highly cycle in Nature, and it is not that nobody knows that but then what excites:

India has roughly 200,000 branded hotel rooms. The United States has 5.5 million. China has nearly 4 million. We have about the same number of branded rooms as Thailand, a country with one-twentieth of our population.

We have done the complete analysis of hotel industry in previous article, if have not read that before reading check that out:

Though if you are even bit familiar with industry, you would get this article. But it is suggested to read that first for better understanding and clarity.

Key Metrics in Hotel Industry

Before decoding the industry’s historical cycles and structural tailwinds, it is critical to understand the economics of the hotel business. Not all hotel companies are built the same, and they are judged by a specific set of metrics.

Key Performance Indicators (KPIs)

• Occupancy Rate: (How full the hotel is)

• ADR – Average Daily Rate (Price per room)

• RevPAR – Revenue Per Available Room

About SAMHI Hotels

SAMHI was founded in 2010 by Ashish Jakhanwala and Manav Thadani - not as a hotel company in the traditional sense, but as a hotel investment and asset management platform.

The idea was simple and contrarian: India’s hotel sector has enormous numbers of underperforming assets - hotels with poor management, wrong brand positioning, or distressed ownership. Acquire them at below-replacement cost. Rebrand under a globally recognized flag. Fix the operations. Hold and compound the cash flows. Then do it again.

More About MD & CEO & Company

This will give you more insights about the company and the management, if you are trying to dig into the company the above link is for you interpret as per your analysis!

This is from magazine named SOH (Soul of hospitality) which seems to be paid due to its wording though questions were really great so not easy to distinguish. Our main motive is to get to know more about promoter and its history, along with their future plans. So, not a bad idea to read.

Well, I could have done that to extend the article through writing this in article, but it did seem to me making sense just copy paste work because it’s already refined…

So, in management analysis I will try to do it from different perspective.

Refer a friend

Business Model

SAMHI Hotels operates on a distinctive Acquisition & Turnaround strategy rather than the traditional greenfield development model used by many peers. Instead of building hotels from scratch, SAMHI identifies distressed or underperforming assets in high-potential markets and transforms them into high-performing properties. This approach is central to its DNA, with approximately 87% of its current hotel inventory developed through this acquisition and turnaround playbook as above discussed.

SAMHI executes this strategy through a four-step value creation loop:

• Identify Dislocation: The process begins by finding opportunities where others see problems. SAMHI scans for under-appreciated assets in micro-markets with long-term demand and high barriers to new supply. It specifically looks for hotels that are suffering from financial stress, poor management, or incomplete construction.

• Acquire Below Replacement Cost: By targeting distressed assets, SAMHI is often able to acquire properties at a significant discount to their replacement cost ­- securing an immediate margin of safety.

• Renovate & Rebrand: Once acquired, the asset undergoes a systematic turnaround process. This involves upgrading the physical product, reconfiguring spaces for better efficiency, and partnering with strong international operators (like Marriott or IHG) to command premium pricing.

• Create Value: Through better management, global distribution systems, and operational efficiencies, the hotel generates higher RevPAR and EBITDA. This quick capex-to-revenue cycle allows capital to work harder and more efficiently than in long-gestation greenfield projects.

Share

Unique Execution Style

SAMHI supports its turnaround strategy with a rigorous operating framework designed to maximize profitability ­- driven by three key enablers:

• Proprietary Technology (SiD): SAMHI uses an in-house data analytics platform called “SiD” (rebranded from SAMHIntel) to drive decision-making. SiD integrates real-time financial and operational data to support everything from acquisition underwriting to day-to-day performance benchmarking.

• Clustered Asset Model: By clustering its hotels, SAMHI utilizes Shared Service Centers to centralize key functions like finance and procurement. This structure minimizes redundancy and enables the company to operate with one of the lowest staffing ratios in the industry, as demonstrated in the comparison below:

Portfolio Overview

SAMHI’s operational portfolio consists of 31 hotels comprising 4,862 keys across India’s key urban consumption centers.

To capture a wide spectrum of demand, SAMHI has built a diversified portfolio spanning multiple price points - from cost-conscious business travelers to high-end luxury guests. Its assets are distributed across three segments:

• Upper Upscale & Upscale:

  This segment includes marquee assets designed to capture high-end travelers, MICE (Meetings, Incentives, Conferences, and Exhibitions), and local dining business.

• Upper Mid-scale:

  This segment acts as a bridge to high-end hotels, offering superior efficiency while leveraging significant market opportunity. Currently, it represents the largest portion of SAMHI’s revenue.

• Mid-scale:

  Focused on the Holiday Inn Express brand, this segment is designed for maximum efficiency with a low footprint and minimal capex per key.

Geographical Presence

SAMHI’s geographical strategy anchors on New India markets - high-density micro-markets within top Tier-1 cities like Bangalore, Hyderabad, Gurugram, and Navi Mumbai. Instead of diluting capital across Tier-2 or Tier-3 regions, the company concentrates on hubs with robust demand drivers, specifically correlating expansion with Grade-A office space absorption and air passenger traffic.

Now, there is more after adding on RARE business in March 2026, it is super exciting!

Management Analysis

SAMHI represents a structural break from the traditional Indian hospitality template. It is an institution run not by bloodline, but by competence. The governance structure is clean and the mandate is clear - this is a team running a disciplined capital allocation engine in my view.

Ashish Jakhanwala (Founder, MD & CEO)

Ashish stands out in the Indian hospitality landscape as a professional founder. He did not inherit a hotel empire; he built one from scratch by convincing global institutions to back his vision.

• Unique Skillset: With over 25 years of experience (including leadership roles at Accor and InterGlobe), Ashish possesses a rare dual competency. He understands the finance of deal-making (identifying value in distressed assets) just as well as the grind of hotel operations (improving efficiencies). This allows him to spot opportunities that pure financiers miss, and pure hoteliers are too cautious to touch.

• Skin in the Game: While his direct equity ownership is low (1.03%), his financial destiny is tied entirely to the company’s performance. He has not sold any share to create personal liquidity; instead, he shared with analysts at the same Capital Markets Day that he even took on personal debt to pay taxes on his ESOPs. His motivation is clear: he only creates wealth if the minority shareholders create wealth.

Strongest Board:

If the management team is the Engine, the Board is the Steering Committee. SAMHI’s Board operates less like a traditional statutory body and more like a high-level Investment Committee.

• Manav Thadani (Non-Executive Director): The Industry Veteran. As the Founder & Chairman of Hotelivate, he is arguably one of the most respected voices in Indian hospitality consulting. Having served on the board since 2011, he provides the strategic helicopter view - ensuring that SAMHI’s acquisitions align with long-term structural trends rather than short-term fads.

• Independent Directors (The Specialists): The independent directors do not just attend meetings; they lead the critical control functions of the company, matching their specific domain expertise to the committee they chair:

  • Aditya Jain (Chair, Audit Committee): A veteran of Lazard (M&A) and Founder of IMA India, he combines deep financial expertise with economic foresight. He ensures the Audit Committee does not just check boxes but rigorously validates the financial reality of the business.

  • Archana Capoor (Chair, Risk Management Committee): With her background as former Managing Director of Tourism Finance Corporation of India, she ensures the company doesn’t just list risks on paper but has concrete plans to handle financial and operational shocks.

  • Michael Holland (Chair, Nomination & Remuneration and IRs): Former CEO of Embassy REIT (India’s first listed REIT). He brings deep expertise in commercial asset management - critical for SAMHI’s office-complex hotel strategy.

  • Krishan Dhawan (Chair, CSR & ESG): Leveraging his deep experience in CSR and ESG leadership roles across various organizations, he drives the sustainability agenda - a critical factor for global institutional investors.

• Institutional Oversight: The presence of Ajish Abraham Jacob (representing Asiya Capital) acts as a governance shield.

Unlike traditional family-run boards, this structure ensures that the board acts as an active guardian of minority shareholders, enforcing a strict mandate of capital protection and Return on Equity (ROE).

To be very honest, this level of board is not even found in Mid-Caps where such an elite players take the governance responsibility, and quality of board is far - far above than any other small or micro-cap!

Interesting Data Points

While top management sets the vision and strategy, profiles of SAMHI’s corporate employees on LinkedIn, and the results tell a clear story: SAMHI is built on financial discipline, not just hospitality flair.

• Financial Pedigree: The office is stacked with CAs, CFAs, and graduates from SRCC, featuring alumni from McKinsey and Big 4s. This confirms SAMHI’s focus is asset turnaround - using sophisticated talent to model acquisitions and optimize capital.

• Deep Functional Specialization: There is a striking consistency in career paths: almost every employee demonstrates deep functional continuity, having worked exclusively in their specific domain (e.g., Finance, Legal, IT) throughout their careers. They are specialists, not generalists.

• Rare Stability: Retention is exceptional ­- out of the 24 profiles I got, 12 have been with SAMHI for more than 5 years. For several key employees, it is the first and only company they have ever worked for, with tenures spanning 10 to 15 years. This deep institutional memory is a massive asset.

The Takeaway: SAMHI operates like a team of financial engineers, leaving the operational grind of running hotels to their Brand partners. This allows the corporate team to focus entirely on the high-value levers: buying right, fixing fast, and creating value.

Capital Allocation

Capital allocation is the ultimate driver of long-term value, described by Warren Buffett as “the most important job of the CEO”.

Acquisitions

The best way to judge management’s skill is to look at their completed work. The Mature Assets (48% of capital), where the turnaround is finished, are generating a healthy 17%–18% ROCE. This proves that when the transformation is complete, the assets generate superior returns.

In contrast, the remaining capital is deployed in assets that are still in the renovation or early ramp-up phase. The ‘ACIC’ and ‘Pending Turnaround’ portfolios (41% of capital) are currently yielding between 4.5% and 6.5%, while ‘Growth’ assets (7% of capital) are just starting to contribute (0.5%–1.5% ROCE).

Essentially, the high returns from the mature hotels are currently masked by the large portion of the portfolio that is yet to fully ramp up - creating a clear path for the consolidated ROCE to expand to the mid-teens as these projects mature.

To see this capability in action, let’s look at a specific case study.

Case Study: Sheraton Hyderabad

This acquisition highlights SAMHI’s turnaround prowess. Management renovated and rebranded an under-performing 158-room asset, expanding it to 272 rooms (targeting 326). This transformation drove a massive 9x surge in RevPAR.

Sale of Assets (Capital Recycling)

Management disposes of assets that do not meet their internal ROCE hurdles or lack a clear path to generating a 15% yield. This “Capital Recycling” strategy allows them to exit weak markets and redeploy that cash into high-growth opportunities in core hubs like Hyderabad and Bangalore.

Recent disposals include:

• Four Points by Sheraton, Chennai: Sold for Rs 53.5 crore to reduce debt and exit a non-core micro-market.

• Caspia, Delhi: Sold for Rs 65 crore due to structural unviability.

Let’s analyze the logic behind the Caspia sale to understand management’s capital allocation discipline.

Case Study: Caspia, Delhi

Management decided to sell this hotel for Rs 65 crore rather than attempting a turnaround. The math was simple: the hotel was generating an operating loss of ~Rs 1.5 crore in FY25, with a historical peak EBITDA of only ~Rs 3 crore.

To make this asset viable, SAMHI would have needed to invest an additional Rs 15-20 crore in capex to renovate & rebrand it (likely to Fairfield by Marriott). This would raise the total opportunity cost to ~Rs 80 crore (Sale Price + Capex). To achieve their target of at least 15% ROCE on that capital, the hotel would need to generate an EBITDA of Rs 12-14 crore — a 4x jump from its historical peak.

Why was this unachievable? The failure was structural and geographic. The hotel is located in North Delhi, geographically isolated (~35 - 40 Km) from the major corporate hubs of Gurugram and Noida.

Unlike those hubs, North Delhi is driven by social demand (weddings/events) rather than corporate travel. However, being part of a mixed-use development, the hotel was caught between a wrong location for business travelers and a wrong product for social events - leaving the asset with no path to a 15% return. Selling it was the correct capital allocation decision.

Future Growth Drivers

SAMHI is undertaking a significant expansion plan to add approximately 1,500 rooms to its current operational base of 4,862 keys - ~30% increase in inventory. This growth is driven by a combination of new openings as well as the expansion and rebranding of existing hotels.

As highlighted in the chart below, this pipeline is heavily skewed towards the Upper Upscale & Upscale segment, which is projected to increase from ~22% of the portfolio today to ~38% by FY30+. By upgrading specific hotels to premium brands (such as rebranding Four Points to Tribute Portfolio) and launching new hotels in high-demand markets, SAMHI is shifting its mix to capture higher ARR and better margins while also increasing the cyclicity.

Subscribe now

1. W Hotel, Hitec City, Hyderabad (170 Keys)

This project represents a unique Office-to-Hotel conversion, demonstrating SAMHI’s ability to unlock value from unconventional assets. Located on the main arterial road of Hitec City - Hyderabad’s premier tech hub - these 170 keys - luxury property is being developed under a long-term variable lease model. This structure is capital-efficient, reducing the upfront cash burden while allowing SAMHI to tap into the high-spending demand of the district. The choice of the “W” brand (a luxury brand by Marriott) positions this asset to command significant premiums over standard business hotels in the vicinity.

2. Westin & Tribute Portfolio, Whitefield, Bangalore (362 Keys)

This development creates a massive Twin - Hotel Complex in Whitefield, one of India’s most important commercial micro-markets.

• Tribute Portfolio (142 Keys): SAMHI is renovating and rebranding this asset from Trinity (Upper Mid-scale) to Tribute Portfolio (Upscale), moving it up the value chain to capture higher ARR.

• The Westin (220 Keys): On the adjacent land, SAMHI is constructing a new Westin hotel (Upper Upscale).

• The Synergy: By operating two distinct brands in one complex, SAMHI can cater to the different price points at same time while sharing back-end costs (kitchens, staff, management) leading to superior operating margins as I said (Clustered Asset Model).

3. Rebranding & Expansion of Existing Hotels

A core part of SAMHI’s strategy is maximizing the potential of its existing assets to extract higher value without significant execution risk. This involves two distinct levers: rebranding current hotels to premium brands and expanding the capacity of high-performing assets.

• Rebranding: SAMHI is upgrading the Four Points by Sheraton in Pune and Jaipur to Courtyard by Marriott and Tribute Portfolio, respectively. This is not just a name change; it allows SAMHI to reprice the inventory significantly higher, as these new brands command a superior market perception and ARR compared to the previous brand.

• Expansion: SAMHI is adding inventory to its strongest performers where the infrastructure is already paid for. For instance, the Sheraton Hyderabad is adding 42 rooms, and the Fairfield by Marriott Chennai is expanding by 86 rooms. This growth is highly capital-efficient because the land, lobby, and support staff are already in place — leading to a much higher ROCE on the new incremental rooms.

4. Navi Mumbai & Hyderabad Financial District

Two recently announced projects provide visibility well into FY29-30+:

• Mid-scale Hotel, Financial District, Hyderabad (260 Keys): This project is structured as a capital-efficient variable lease, minimizing upfront investment. It strengthens SAMHI’s position in the Financial District by adding a Mid-scale hotel to its existing portfolio, which already includes the Sheraton (Upscale) and Fairfield by Marriott (Upper Mid-scale). This addition allows SAMHI to offer a complete range of price points within the same micro-market, enabling it to capture demand across all customer segments.

• Westin & Fairfield by Marriott, Navi Mumbai (~700 Keys): This is the crown jewel of the long-term pipeline. Located near the newly operational Navi Mumbai International Airport and DY Patil Stadium, this dual-branded hotel will be a massive revenue engine. With ~700 rooms, it will be the largest hotel asset for SAMHI - and one of the largest in Navi Mumbai - perfectly timed to capture the demand explosion from the new airport in the coming years.

SAMHI Hotels × RARE India

On 5th March 2026, SAMHI Hotels quietly announced a deal most people ignored. Well, it shouldn’t have been.

SAMHI is acquiring a 70% stake in RARE India a 20-year-old platform of curated, experience led hotels across India, Nepal and Bhutan for just ₹47 crore.

Think of RARE as the OYO but in different niche. Founded in 2003 by Shoba Rudra, it curates small experience-led properties rooted in place, story and sustainability. Forts and palaces in Rajasthan. Wildlife lodges in Madhya Pradesh. Hill retreats in Himachal. River cruises in Assam. Jungle camps in Uttarakhand.

Every property is hand selected. 67 hotels. 990 rooms across 15 states and 3 countries. Average daily rate of ₹25,000. More than 70% of properties operate above that threshold.

That average daily rate is, for context, higher than SAMHI’s entire Upper Upscale and Upscale segment ADR of ₹9,748 in FY25. And SAMHI just bought 70% of this platform for ₹47 crore.

At first glance, this looks like a small acquisition. It’s not.

But the real story lies in what could happen next.

There is a proposed partnership where RARE becomes the exclusive platform for a new “Outdoor Collection” under Marriott International’s Bonvoy ecosystem. If executed, this plugs RARE into a 200M+ global loyalty base solving the biggest problem for boutique hotels: distribution.

Important: this is not live yet. It’s an option, not a guarantee.

If it works:

If it doesn’t:

Strategically, this changes SAMHI’s identity.

Until now, it has been largely a business hotel play (office hubs, corporate demand).

RARE adds luxury leisure a completely different demand cycle, higher pricing power, and diversification.

That’s what makes this deal interesting because have not even priced it yet so any positive on this front can lead to overnight PE explosion.

Risks

1. Inherent Industry Cyclicality

The hospitality sector is deeply tied to the broader economy. Any slowdown in GDP growth or discretionary spending can directly impact Occupancy levels and ARR, reversing the operating leverage that currently works in the company’s favor.

2. Elevated Leverage

While the debt profile is improving, SAMHI remains one of the more leveraged players in the industry. High interest costs continue to depress reported PAT. The thesis leans heavily on management’s ability to reduce Net Debt/EBITDA through internal accruals; any failure to deleverage would be a key red flag.

3. Execution Risk

A significant part of the growth narrative depends on the successful turnaround of the ACIC portfolio and timely completion of new hotels. Any delays or cost overruns in these capital-heavy projects would drag return ratios (ROCE) and postpone the anticipated earnings growth.

4. Supply Overhang from PE Exits

A large portion of equity is held by institutional investors (like Steinberg, ACIC etc.). As the share price re-rates, these entities may look to book profits. Periodic block deals or selling pressure could create a temporary ceiling on the share price, regardless of fundamental performance.

The risks in the company are like the ones that if happens it just destroys whole company this could be the one of main reasons for their so low PE compared to peers not including the short-term (2-3 years) risk of PE exits overhang.

Leave a comment

Conclusion

SAMHI stands out as a unique special situation within the Indian hospitality sector, distinct from the traditional development-led models. The company has successfully navigated its most difficult phase - surviving the crisis and repairing the balance sheet and is now entering a new phase “SAMHI 2.0” as Ashish Jakhanwala termed it in one of the latest concall.

As the portfolio matures and operational efficiency improves, the twin engines of operating leverage and deleveraging are set to drive non-linear earnings growth.

While execution risks persist, the current valuation provides a significant margin of safety that largely ignores this improved quality of earnings. For investors, SAMHI represents a classic arbitrage opportunity: high-quality assets bought at distressed prices, now ready to deliver superior returns on capital.

If you like the content

Subscribe now

Disclaimer: This article is for educational purposes only and is not investment advice. I am not a SEBI registered advisor. Please consult a financial advisor and do your own research before investing. Equity investments are subject to market risks.

Analyzing companies takes time, patience, and a lot of reading between the lines. My goal is to cut through the market noise and bring you high-quality, data-backed analysis. If you found value in this breakdown, consider subscribing to the newsletter. You’ll get my next deep dive delivered straight to your inbox - no fluff, just pure analysis.

Another piece of my work:

Not Just a Consumables Company Anymore

One of the Most Overlooked Sector - Dairy

Reginal Chain Quietly Scaling in North India

Reopening the File on Canara Robeco AMC

Recommend Me to Other Writers

Share Capital Conviction

But first let me clear you that I won’t be covering any company each and every quarter like a maniac, I would do that if there will be any major changes etc. As I say every time, I like compounders, and quarterly results are noise for it. Of course, I would try to keep it open about my major investments through may be an annual report on it. That’s a different topic to discuss. Let’s get back to the track now.

Well, if you don’t have prior knowledge about the company, do check this out first:

Just a brief analysis of how company was formed:

The company has Joint Venture with a shareholding structure where Canara Bank owns 38% and OCE (ORIX Corporation Europe) holds 37%. They were incorporated in 1993 and are the 2nd oldest asset management company in India. Canara Bank is a scheduled public sector commercial bank, was founded in the year 1906 as a private entity and became a nationalized bank in 1969. And ORIX Corporation Europe is subsidiary of ORIX Corporation, which is headquartered in Tokyo, Japan.

Our main topic of discussion would be Canara Robeco AMC, but we would slightly touch upon the Robeco group of ORIX Corp. not the whole ORIX group because the group as whole is in various parts like lending, private equity, real state etc.

The total MAAUM generated through Canara Bank branches is about 11.00% of its total MAAUM. They also benefit from OCE’s global expertise in investment management, product management, risk management, and other operational departments, which helps us to build strong corporate governance standards, risk mitigation strategy, and diversification of product portfolio.

Topics Covered

• Results

• The Shareholding Changes

• Robeco’s Global Struggles

• Potential Businesses Power

• First Mover Advantage in AMCs

• Mr. Narula Succession Question?

• Best Risk-Reward in the AMC Space??

Noisy Results

The stock fell 4% on results day and headlines screamed "profit decline." In reality, Q4 PAT dropped 22% sequentially almost entirely because of a spike in other expenses - almost certainly SEBI's skin-in-the-game mark-to-market adjustment on fund manager investments, which swings with quarterly market volatility, not with business health. Also, the new NFO expenses that should get normalize in next quarters. Strip that out and the quarter was unremarkable in the best way - revenue up 13% YoY, costs actually down 10% sequentially, AUM steady at ₹1.06 lakh crore with QAAUM up 14% YoY. Full year numbers were clean: Revenue ₹425 crore up 17%, PAT ₹204 crore up 7%, debt-free balance sheet, ₹2.50 dividend declared.

The one genuine concern worth carrying into FY27 is that expenses grew 23% annually against 17% revenue - that's operating leverage moving in the wrong direction and needs watching. But the AMC is equity focused so it is not very rare thing to happen, this kind of things happen during bear phases in this kind of AMCs when bull run gives them a huge runway side and high margins time.

Overall If I conclude the results, it was a complete noise, but this is a surface level knowledge, let’s go deeper into ocean trying to reach the Mariana Trench!

What’s your take was this result was really a noise or a signal for you:

Leave a comment

The Shareholding Changes

When CRAMC’s IPO dropped in October 2025, the shareholding pattern changed significantly earlier it was 51% with Canara Bank & 49% with Robeco (ORIX group). Now the number has changed, it is 38% and 37% with Canara and Robeco respectively. Where public float is 25% obviously.

It gets more interesting. RBI requires Canara Bank to reduce its stake to 30% or below by October 2029. That’s 8 percentage points more to shed - a small, near-complete transition. When those 8% move, one of four things happens:

• Institutional investors absorb it and bring analyst coverage

• Robeco group buys it and becomes the dominant strategic partner

• New strategic investor comes in.

• Open Market Selling.

First three outcomes are net positive. While 4th one depends on sentiments but also the least likely according to me. Second one is most bullish signal for the shareholders.

The PSU discount thesis is being dismantled in real time. The market just hasn’t updated its model yet. Or maybe it has because there is one more thing below in the article.

Robeco’s Global Struggles

Here’s where intellectual honesty matters.

Robeco - CRAMC’s 37% partner - has not had a great five years globally. AUM peaked at €187 billion at end-2021, collapsed to €156 billion by end-2022, and only recovered to €197 billion by end-2024. In 2022 and 2023, they suffered net outflows of €9.4 billion and €3.7 billion respectively. Operating profit fell from €73.5 million in H1 2021 to just €29.9 million in H1 2023.

That’s a company that was bleeding while its Indian JV was quietly posting 41% profit CAGR.

Little Nuance: Robeco’s struggles were almost entirely a European wholesale distribution problem tied to the ESG backlash. They over - indexed on thematic sustainability funds - clean energy, water, gender equality - that underperformed when rates rose sharply post - 2021. European pension funds questioned the ESG fee premium. The US political environment turned hostile toward ESG as an investment label.

Share

None of this has any direct bearing on how CRAMC runs equity and debt schemes in India. Indian retail investors aren’t buying Robeco’s European thematic products. What Robeco brings to CRAMC is investment process discipline, governance frameworks, and credibility - and those things are unaffected by whether Scandinavian pension funds pulled money from Robeco’s ESG funds in Amsterdam.

Indirect Risks: A financially pressured global parent may give the India JV less management bandwidth, and there’s a low probability scenario where Robeco eventually treats the 37% stake as an asset to monetize. But given that CRAMC is one of the few genuinely profitable, growing parts of the ORIX network right now, exiting India just as the Indian MF industry hits its stride would be strategically bizarre.

Opportunity: Well, the other side becomes that the group sees the potential on Indian landscape and tries to double down and gets bit aggressive. Given the company has global relationship, it brings more to the table for CRAMC in this. May be acquiring more shares from Canara Bank as they have to sell 8% more…

Potential Businesses Power

This is the most important section of this piece.

The market is pricing CRAMC at ~25x PE as a traditional mutual fund company with ₹1.06 lakh crore AUM. That’s the entire valuation.

Here’s what’s sitting at zero in that price but because they have not entered in it, yet I have seen this through perspective of first mover advantage for others:

ETFs

CRAMC has not launched a single ETF. Not one. While the rest of the industry built massive passive businesses - Nippon has a dominant ETF franchise, HDFC runs multiple index and gold ETFs, SBI cornered EPFO mandates - CRAMC has been entirely absent from India’s fastest-growing product category.

In ETFs, first mover advantage is there. It’s a liquidity flywheel - the ETF with the highest AUM gets the most trading volume and gets tops on broker UI, which creates tighter bid-ask spreads, which attracts more institutional buyers, which grows AUM further. Take the example of gold for example, the most value captured was by only three AMCs - Nippon, HDFC and ICICI.

Share Capital Conviction

But CRAMC has something interesting that most new ETF entrants don’t - Canara Bank’s 9,000+ branch network and deep PSU institutional relationships. PSU Bank ETF or Infrastructure ETF distributed through Canara Bank branches to government employees, cooperative banks and PSU treasury desks is not a generic product. That’s a differentiated product with a captive distribution moat. Just an example!

The infrastructure to launch these ETFs are minimal. This is just a SEBI filing that too to an Institutional AMC, not a multi - year manufacturing thing. The only reason it hasn’t happened is management conservatism - and on that front, Section 5 has something important to say.

PMS

I don’t have to show you the numbers that how much growing category the PMS is, and it is a multiyear theme too not the 1–2 years boom.

Portfolio Management Services minimum ticket is ₹50 lakh. Fee structures are 1.5–2.5% management fee plus profit sharing - significantly richer than mutual fund TERs. India’s HNI and UHNI wealth is compounding fast, and PMS AUM has been growing faster than the mutual fund industry overall as said earlier.

CRAMC’s fund management team is demonstrably capable. Shridatta Bhandwaldar was named Best Fund Manager by ET Wealth in 2025. The investment process, the research infrastructure, the brand - all present. What’s missing is the registration and product launch.

Unlike ETFs, first mover advantage in PMS is minimal. HNIs switch on performance, not loyalty. CRAMC entering PMS late is not a structural disadvantage - the playing field resets with every performance cycle like we see in equity mutual funds.

AIFs

Alternative Investment Funds are the highest-fee, fastest-growing segment in Indian asset management. Category II AIF fees are typically 1.5–2% management fee plus 20% carry on returns above the hurdle rate. The AIF market is projected to grow at 22%+ CAGR through 2030 and I am being on the conservative side.

Nippon runs AIFs across private equity, private credit, real estate, and venture capital. Similarly, ICICI, HDFC, Kotak - all present. CRAMC - entirely absent.

Even a small AIF book would add a completely new high-margin revenue line that doesn’t show up anywhere in current analyst models for CRAMC.

The compounding effect: Conservative estimates of ETF, PMS, and AIF contribution over 5 years could add ₹200 – 360 crores in incremental annual revenue on top of current revenue of ₹424 crore. That’s potentially doubling the revenue base from product expansion alone, before counting the organic growth of the existing MF business.

Singapore Offshore Advisory

CRAMC runs a SEBI-registered offshore advisory business out of Singapore, providing investment advisory services to foreign portfolio investors and offshore funds looking to deploy capital into Indian equities. This sits quietly on the books, generates fee income without any incremental AUM on the domestic count, and benefits directly from every dollar of global institutional money that rotates into India.

The significance isn’t the current revenue - it’s the structural positioning. As India’s weight in global Equity Market indices increases and foreign allocation to Indian equities grows over the next decade, an existing Singapore advisory entity with regulatory approvals already in place is not a small thing to build from scratch. Most new AMCs wanting to tap offshore flows have to spend 2–3 years getting the entity registered, building compliance infrastructure, and establishing relationships with global allocators. CRAMC already has the plumbing & also the ORIX can add this significantly.

The market is pricing none of this. Well, why should it when the mgmt. says we are not focusing on it except the last one.

Mr. Narula Succession Question?

Well, the market is never entirely wrong about anything, it just discounts the risk sometimes higher or sometimes lower.

Mr. Rajnish Narula has been MD & CEO since 2007 - 18 years at the same company, which is extraordinary by any standard in Indian financial services. He’s now in his 60s, almost certainly in his second to last term given SEBI’s norms around tenure and age limits for key management personnel at regulated entities.

On paper this reads as a risk. In practice, it’s more complicated.

Risk: An 18-year CEO who hasn’t launched a single ETF despite watching the passive investing boom unfold across his entire tenure is not someone likely to suddenly turn aggressive in year 19. Institutional conservatism doesn’t self-correct. The product gaps discussed above - ETF, PMS, AIF - didn’t happen under Mr. Narula not because the opportunity was unclear, but because the appetite wasn’t there.

Succession Risk Compounds This: if the next CEO is another internal consensus pick from the same cultural mold, the conservatism just continues under a new name.

Catalyst Side: Very long-tenured conservative CEOs often spend their final term trying to cement a legacy that looks bigger than steady stewardship. Narula has built an excellent business - high ROE, low leverage, quality fund performance, clean governance. But “excellent small AMC” is not a legacy that gets remembered. Launching CRAMC’s ETF business, registering a PMS, or filing for an AIF structure before handing over would be. There’s a non-trivial probability that the next 2–3 years see more product action from CRAMC than the previous 10, precisely because the clock is running.

And then there’s the successor dynamic. Whoever comes next - whether an internal candidate from the fund management side or an external hire with Robeco’s blessing - arrives with a blank slate, no legacy conservatism to protect, and an institutional shareholder base (now that the company is listed) actively asking uncomfortable questions about product breadth. That is a structurally different environment for a new CEO than what Narula inherited in 2007.

CEO transitions at conservative, quality financial businesses that have underinvested in product expansion are historically one of the most reliable re-rating catalysts in financial services. HDFC Life, Bajaj Finance, Kotak Mahindra Bank - each went through periods where a new leader broke from the conservative playbook of the founder era and the market re-rated accordingly.

The Narula succession is not a binary risk. It’s a variable with a wide outcome distribution - and the mean of that distribution is more positive than the bear case suggests.

First Mover Advantage in AMCs

When I started researching the answer was obvious to me that it should be highly sticky but as I dig deeper, I found it was not the case with Institutional Investors and vice versa with retailers.

So, the answer now: depends entirely on which product.

In traditional active mutual funds - almost no first mover advantage. An investor can switch funds in three clicks with zero penalty after one year. Platforms like Groww and Zerodha rank funds by returns, and retail money follows those rankings ruthlessly. If you don’t perform, you lose AUM. Full stop.

This is actually a feature, not a bug, of the asset management industry. Capital is supposed to flow toward the best risk-adjusted returns. And it largely does in India’s maturing MF market.

• In ETFs - strong first mover advantage exists, but only in the most liquid benchmark categories. That window is largely closed. For thematic or sector ETFs, the field is still open. And it’s not gone be filled in some years, it can take a long runway.

• In SIP folios - weak stickiness. Once an investor has been running a SIP for five years and forgotten about it, inertia keeps them invested. But this is not a moat - if a distributor actively nudges a switch, it happens. SIP stickiness buys time; it doesn’t guarantee permanence. The number shows that nearly 90% of investors stop their SIP in first 5 years. March only saw 100% SIP Stoppage ratio means the amount of SIP inflows were equal to the amount of SIP people stopped.

• In Institutional segments - essentially zero first mover advantage. These are the most performance-driven, most advisor-guided, least loyal investors in the system. Being first means nothing. Being best is everything.

The honest principle underlying all of this: In asset management, sustained alpha generation is the only truly durable competitive advantage. Everything else - brand, distribution, PSU relationships, first mover position - is a temporary buffer that buys time. If you don’t deliver returns, the buffer erodes. Well, it can be that you underperform in short term, but the value is only in long term. Basically, it is now a commoditized product.

HDFC AMC did not reach ₹7.5 lakh crore AUM by being first. UTI was first. LIC MF was early. HDFC got to the top by being consistently good across multiple market cycles. Consistency of performance is the moat. Everything else is marketing.

Leave a comment

Conclusion

Let’s put it all together without the usual analyst hedging.

At ₹255 and ~25x PE, CRAMC offers something genuinely rare in the Indian listed financial space - a high-quality business at a meaningful discount to peers, with multiple optionality that are entirely unpriced.

The Bull Case Catalysts:

• 25x PE vs 40x for HDFC etc. on comparable ROE (30%+) and superior historical earnings growth (41% PAT CAGR over 5 years)

• Canara Bank’s stake already at 38% - PSU dominance getting skewed.

• RBI-mandated 30% cap by 2029 forces the remaining overhang resolution.

• ETF, PMS and AIF at zero current revenue but fully buildable.

• Institutional shareholder pressure are new accountability mechanisms that didn’t exist pre - October 2025

• Robeco’s improving financial health (H1 2025 operating profit recovering to €65 million) reduces the parent-pressure risk.

Subscribe now

The Bear Case Catalysts:

• Mr. Rajnish Narula is a conservative 18-year CEO who has watched the ETF industry grow for a decade and chosen not to enter - past behavior predicts future behavior. He is now approaching his likely final term, which introduces genuine succession uncertainty on top of the conservatism risk.

• FY26 showed PAT growing only 7% with expenses up 23% - there may be more this kind of things if they enter into new segments.

• Robeco’s global struggles are stabilizing but not over.

• AUM market share is 1.5% stagnant from years to this range, we have talked about reasons in our previous CRAMC article, but risk is a risk.

The hinge variable is management action, not business quality. The business quality is not in question - it’s demonstrably excellent. The question is whether CRAMC uses its listing, its JV structure, and its upcoming Canara Bank stake reduction as catalysts to finally expand beyond a single-product AMC.

Watch the FY27 management commentary specifically on three things: any mention of ETF filing with SEBI, any PMS registration announcement, and the timeline and mechanism for Canara Bank’s next stake reduction below 38%. Those three data points will tell you whether the optionality gets exercised or quietly expires.

Share Capital Conviction

This is not investment advice. This is an analytical framework built from public information, designed to help you think through a complex investment thesis more rigorously than a typical equity research note would. Do your own work before making any investment decision.

Do like and comment down for continuation these kinds of articles on different companies.

Before Starting, I just want to let you know that I believe more in compounding stories rather playing in cyclicals. I don’t have investment in this sector as of now…

Then why making an article on this: Because just to keep my inner curiosity feeding. I love hotel as a sector to learn about, not to invest or run the hotel myself…

Hotel Industry is highly cycle in Nature, and it is not that nobody knows that but then what excites everybody:

India has roughly 210,000 branded hotel rooms. The United States has 5.5 million. China has nearly 4 million. We have about the same number of branded rooms as Thailand, a country with one-twentieth of our population.

If you think rationally, it is clearly gone be long term theme along with some upcycles and downcycles. There may be 50% drawdown in between but when cycle it bursts out.

Think of this, the country with largest population, with one of the greatest pilgrim tourism spots, with growing GDP, with hill stations and so much…

So back to the main topic, in this deep dive, we will decode the mechanics of the hotel industry, analyze the historical cycles that brought us here, and map out the structural tailwinds that suggest we are still in the mid-stages of this upcycle.

If you don’t like this kind of sector, I recommend:

Article on Poly Medicure!

The company is poised to do well in future when dust settles…

Before we began to go understand the industry in deep, we should analyze the business model of different of hotel businesses along with their unit economics.

Business Models

Hotel companies typically operate under mix of four models. The key difference to understand between them is in who owns the real estate versus who manages the daily operations.

Let’s look at the below chart to understand it in go.

As we spoke earlier, the Indian hotel industry is often viewed as one single sector but in reality, hospitality companies operate with very different business models. Let’s break down the business models of key players IHCL, Lemon Tree Hotels and one interesting one SAMHI Hotels.

• IHCL: IHCL operates on a brand first approach. With powerful brands like Taj, Vivanta and Ginger the company increasingly prefers an asset-light model where it manages hotels owned by others. IHCL earns through room revenue, food & beverage and management fees. Its strength lies in brand trust hotel owners are willing to pay IHCL to operate their properties.

  • Model: Brand + management fees

  • Strength: Scalable with lower capital risk

• Lemon Tree Hotels: Lemon Tree focuses on mid - scale and economy hotels for business and domestic travelers. The company is rapidly moving towards an asset-light management and franchise model allowing faster expansion without heavy investment. Standardization and cost control are central to its business.
  

  • Model: Mid-market hotels + management contracts

  • Strength: High scalability and efficiency

• SAMHI Hotels: SAMHI follows a pure asset heavy approach. It owns hotel properties and partners with global brands like Marriott and Hyatt to operate them. Revenue comes from hotel operations while brand operators earn management fees. SAMHI’s business resembles hospitality-focused real estate platform.
  

  • Model: Hotel real estate ownership

  • Strength: High operating leverage

    This is the most interesting one with in my view currently high upside potential with low downside risk.

    I am thinking to write on this, what’s your take:

Key Metrics in Hotel Industry

Before decoding the industry’s historical cycles and structural tailwinds, it is critical to understand the economics of the hotel business. Not all hotel companies are built the same, and they are judged by a specific set of metrics.

Key Performance Indicators (KPIs)

• Occupancy Rate: (How full the hotel is)
  This tells you what percentage of rooms are filled.
  If a hotel has 100 rooms and 70 are booked, occupancy is 70%.
  Higher occupancy = more rooms sold.

• ADR – Average Daily Rate (Price per room)
  This is the average price at which rooms are sold.
  If total room revenue is ₹70,000 from 70 rooms, ADR is ₹1,000.
  Higher ADR = better pricing power.

• RevPAR – Revenue Per Available Room
  This combines occupancy and pricing.
  It tells you how much revenue each room generates, whether it’s occupied or not.
  RevPAR = Occupancy × ADR
  This is the clearest indicator of hotel performance.

Historical Cyclicality

The Indian hotel industry offers a textbook case of capital cycles, and to appreciate the current opportunity, we must first look at how the sector has evolved through its past highs and lows.

We have moved from the “irrational exuberance” of 2003-2008 to the oversupply and weak demand, and finally, to the disciplined recovery we see today.

1. FY96–FY02: The Long Slump

   This was a prolonged period of sluggishness driven by weak economic growth and limited infrastructure. With low returns and restricted capital, new project announcements were scarce - setting a low base for the industry.

   ---

2. FY03–FY08: The Bull Run

   Strong GDP growth and economic reforms triggered a powerful upcycle, driving up demand for both business and leisure travel segments. This surge in demand pushed metrics to lifetime highs, with Occupancy hitting 71.5% and ARR peaking at ~Rs 8,000. These strong fundamentals attracted a massive wave of new investment.

   ---

3. FY09–FY13: The Supply Overhang

   The party ended abruptly. The Global Financial Crisis (GFC) crushed demand just as the massive supply pipeline planned during the boom years hit the market. This “double whammy” of oversupply and weak demand severely suppressed room rates and profitability.

   ---

4. FY13–FY20: The Gradual Rebound

   As new supply additions slowed due to weak sentiment, demand began to recover steadily, driven by domestic travel and macro stability. Eventually, demand growth started outpacing supply, leading to a gradual improvement in Occupancy and ARRs.

   ---

   Leave a comment

   ---

5. FY20–FY22: The Black Swan Event

   Covid-19 came as Black Swan Event, especially for the hospitality sector, resulting in Occupancy and ARR hitting multi-decadal lows. The collapse in travel forced the industry into survival mode, with a focus on cost optimization and the deferral of capex plans.

   ---

6. FY23–FY25: The Strong Recovery

   The sector has recovered sharply - driven by pent-up demand, limited new supply (due to deferred capex during the pandemic), and increased spending in business and leisure travel. As a result, both occupancy and ARRs increased significantly. Coupled with this, the cost optimization measures taken during the pandemic have led to high growth in profitability.

Structural Tailwinds & Growth Drivers

The Indian hospitality sector has transitioned from recovery mode to a structural growth phase. This upcycle is not driven by temporary factors, but by a fundamental mismatch between restricted supply and expanding demand, bolstered by growth in business and leisure travel spend and improved infrastructure across airports and national highways.

1. The Demand-Supply Mismatch:

   The primary driver of this upcycle is persistent imbalance where demand growth consistently outstrips supply additions.

• Overall Market Dynamics: According to industry estimates (Horwath HTL), the supply-demand equation has shifted favorably. While supply is projected to grow at a CAGR of ~8.4% between FY25 and FY30, demand is expected to race ahead at ~9.6%.

• Acute Shortage in Key Markets: This mismatch is most pronounced in Tier-1 markets like Hyderabad, Bangalore, and Chennai. As shown below, demand growth in these business hubs consistently outpaces incoming supply, creating a structural shortage that supports sustained occupancy and strong pricing power.

2. Strengthening Business Travel & MICE Momentum:

   The resurgence in business travel is not merely a return to pre-COVID norms, but a structural expansion driven by India’s growing dominance as a global office hub.

   Though it again deaccelerated as due to these geopolitical issues.

   ---

• The GCC Effect: India is witnessing an explosion in Global Capability Centers. The number of GCCs is expected to scale from ~1,700 in FY24 to over 2,100+ by FY30, employing 2.5 - 2.8 million professionals. This is directly linked to hotel demand - every new GCC creates a recurring stream of high-yield corporate travel for leadership visits, training, and project migrations.

• Record Office Absorption: Office leasing, a key leading indicator for business travel, remains robust. Gross leasing activity is projected to hit 89.6 million sq. ft. by 2026F, surpassing 2019 levels of 67.8 million sq. ft. Cities like Bangalore and Hyderabad are transforming into some of the largest office markets globally, ensuring a steady pipeline of corporate room night demand for years to come.

• MICE as a Growth Pillar: This corporate expansion is fueling a sharp rise in MICE (Meetings, Incentives, Conferences, and Exhibitions) activity. With corporates increasing spend on offsites and large-scale industry events returning, MICE is evolving from a seasonal filler to a consistent revenue driver for city hotels.

Share Capital Conviction

3. Structural Shift in Consumption:

   Beyond corporate demand, the industry is witnessing a “consumption upgrade” cycle driven by rising per capita incomes and a structural shift in spending habits.

   ---

• Policy Catalysts: A powerful “policy trifecta” in 2025 has structurally unlocked household wallets. The Feb 2025 Budget raised the rebate limit to Rs 12 Lakh and rationalized slabs - ensuring significant tax savings even for higher income earners, followed by September’s GST rate cuts. Coupled with the RBI slashing the Repo Rate to 5.25% in December, these measures have significantly lowered fixed costs (taxes & EMIs), channeling massive disposable income directly into discretionary sectors like hospitality.

  ---

  • The Rise of Purpose-Led Travel: Travel is no longer limited to the annual family vacation. We are seeing the mainstreaming of specialized segments like wildlife and heritage tourism for experience seekers, wellness retreats for the health-conscious, and a massive boom in spiritual tourism (Ayodhya, Varanasi, etc.), which is driving volume in non-metro hubs.

    ---

  • The Gig Tourism: Spending patterns are shifting from asset accumulation to experiences. This is evident in the surge of wedding tourism (destination weddings) and the new phenomenon of event-led tourism - where thousands travel specifically for concerts (e.g. Coldplay) or major sporting events, creating demand spikes that allow hotels to command premium pricing.

    ---

  • Foreign Tourist Arrivals – The Next Leg: While domestic demand anchors the current growth, Foreign Tourist Arrivals are in a gradual recovery phase. With global connectivity improving, FTAs offer significant upside potential, particularly for the luxury and upper upscale segments in key metros.

4. Infrastructure as a Catalyst:

   India’s massive infrastructure push is structurally unlocking travel demand. The operational airports have more than doubled from 74 in FY14 to 162 in FY25, which significantly improved pan-India air connectivity, making tourist destinations far more accessible. Simultaneously, a ~50% expansion in National Highways to 146,000 kms FY14 to FY24 has catalyzed the “road-trip” leisure segment, making weekend getaways and regional tourism viable year-round.

Conclusion

The Indian hospitality sector is in a sweet spot - demand is structural and supply is constrained, giving existing players unprecedented pricing power. When you combine this with the explosion in domestic tourism, revival of business travel, recent rate cuts and government’s infrastructure push - the macro setup is arguably the best we have seen in decades.

• Get My Personal Watchlist Access for 3 referrals

• Get One Deep Dive (Private) + My Top Bets Access for 10 referrals

• Get Full Portfolio Access + 1:1 Call for 25 referrals

Refer a friend

If you found this useful:

• Share with fellow investors

Share

• What’s your Opinion:

Leave a comment

If you enjoy Capital Conviction, it would mean the world to me if you invited friends to subscribe and read with us. If you refer friends, you will receive benefits that give you special access to Capital Conviction.

How to participate

1. Share Capital Conviction. When you use the referral link below, or the “Share” button on any post, you'll get credit for any new subscribers. Simply send the link in a text, email, or share it on social media with friends.

Refer a friend

2. Earn benefits. When more friends use your referral link to subscribe, you’ll receive special benefits.

• Get My Personal Watchlist Access for 3 referrals

• Get One Deep Dive (Private) + My Top Bets Access for 10 referrals

• Get Full Portfolio Access + 1:1 Call for 25 referrals

Visit the leaderboard

Thank you for helping get the word out about Capital Conviction!

On Sunday, I sat down for more than 2 hours to actually understand how can I deliver better quality work to my members. The last article I wrote, was a complete mess by me, even I am not able to understand the work clearly, if I am even a lit bit lazy. I sincerely apologize to the all the readers reading that. So, now what I have done is to summarize the previous entire article in flow charts and easy way and of course covering 2nd Part in Detail so you can actually say it as a full analysis. Hope you enjoy it now, looking forward for your feedback!

Disclaimer: This article is for educational purposes only and does not constitute investment advice. Please do your own research or consult a financial advisor before making any investment decisions.

Topics Covered:

• About Poly Medicure

• Product Portfolio

• Financial Performance

• Balance Sheet Analysis

• Management Quality

• Growth Drivers

• Acquisitions

• Valuation Check

• Summary Insights

• Scorecard

• FAQs

Present in 125+ countries, Poly Medicure makes mainly single - use medical devices for hospitals. It is now transitioning from low value IV line consumables into high complexity cardiology and renal devices - climbing the margin and moat curve.

For now, at its core, it is still a business built on high-frequency, repeat-use consumables embedded into every hospital workflow.

Segmentation

Renal Care: Four Sub Products

Value Chain

New product 1: IVL - Intravascular Lithotripsy

Some arteries become calcified and hard like stone - regular balloons and stents cannot expand inside them. IVL uses sonic shockwaves to crack the calcium first, making the artery pliable so normal treatment can succeed.

New product 2: DEB - Drug Eluting Balloon

After opening a blocked artery, it often narrows again. A drug-eluting balloon prevents this by releasing medicine directly into the artery wall during inflation - then it’s removed, leaving nothing behind.

New product 3: Dialysis Machines

Previously, Poly Med only made dialysis consumables. Now it’s moving into the machines themselves - a higher-ticket product that also locks in downstream demand for its own bloodlines and consumables.

This shifts Poly Med from a product seller to a system-level participant, where every machine placed creates recurring demand for consumables. This means they are directly entering to the complete value chain with the help of their previous goodwill in market.

Share Capital Conviction

Product Portfolio

This just goes off to show their so much diversified product portfolio. As such, I don’t have anything special to comment on this, but these are the products that are actually made by them.

Financial Performance

You see numbers are saying a completely false story if you go to recent numbers, margin drop from 26% → 23%. Sales growing at single digits in recent. This has led to complete stock derating from 100 PE to 40s PE.

Subscribe now

There is not even a single solid reason to justify that there are any long threats caused by this except some short-term volatility that will be there.

Now let’s move on to Return Ratios:

In this, we would check the ROCE instead of ROE because they generally have great cash piles in general so it may give false conclusion about the business!

• ROCE: The company is maintaining healthy ROC of around 20% from last 5-7 years. So, their capital allocation as of now has been great.

• Cash Flows: The company operates at OCF positive since more than decade! The company operates at more than 80% CFO/OP easily, this year it’s low at 73% due to acquisition and cash outflow from this.

• Working Capital Days: Poly Medicure operates with moderate working capital intensity, which is typical for a manufacturing and export oriented medical devices business.

  • Receivables have been declining year by year that’s a really good sign.

  • Inventory remains structurally higher due to product breadth and regulatory requirements also the new heavy devices may increase it slightly more.

  • Payables provide limited offset

Balance Sheet Analysis

The company is nearly debt free with strong reserves. The fixed assets of 635 Cr. have more than doubled to 1439 Cr. in 2.5 yrs of span. Showing the rapid scale expansion of company in newer segments. The company has liquid position of more than 800 Cr. (after recent acquisitions). In other assets, it is the inventories that has been build which overall will get better once the asset turns increases.

Conclusion, the balance sheet is very clean.

Management Quality

So, to analyze management we would divide it into three parts:

• Execution Part: Management quality becomes visible through how steadily the business has been built over time. The company’s execution track record reflects a clear pattern - growth has been consistent, margins have improved gradually, and new segments like renal and cardiology are being scaled in a phased manner rather than being rushed. This kind of progression usually indicates strong operational control, where expansion is aligned with capability rather than ambition alone.

• Communication & Confidence: What also impressed me is the way management communicates. The tone remains largely operational - focused on capacity additions, product expansion, and export growth - without excessive forward-looking hype. Even when discussing areas like working capital or expansion, the messaging stays measured and grounded. This builds a certain level of confidence, as management appears more focused on executing the business than narrating it, which is a positive signal in manufacturing led companies.

• Governance Issues & Promoter Holding: From a governance standpoint, the structure appears stable and aligned. The company continues to be promoter-led with meaningful ownership, and there are no visible signs of governance-related concerns. Growth has largely been organic, with acquisitions being selective and strategically aligned not a rush buy or something. This suggests that the management’s incentives remain closely tied to long-term value creation rather than short-term gains.

Growth Drivers

1. Structural Demand from Consumables
At its core, this remains a consumables business where products are used repeatedly across medical procedures. Demand is therefore linked to patient volumes rather than economic cycles, creating a predictable and steady growth base. So, it is more of cash cow for business leading from front for providing growth.

2. Domestic Expansion
With presence in 125+ countries, exports continue to be a major growth lever. But Management also acknowledges that they are seeing good growth traction in domestic market. The GDP of India is growing so is the healthcare so is their GDP contribution and spending. You can take the Idea that Renal Care is still only done in India not in foreign as of now and have started contributing 10% of total revenue.

3. Moving Up the Value Chain
The shift from basic consumables to higher-complexity segments like cardiology and renal care is a key structural driver. These segments offer higher margins, stronger entry barriers, and better product differentiation.

4. Capacity Expansion & Operating Leverage
Ongoing investments in manufacturing capacity and automation allow the company to scale efficiently. As utilization improves, this leads to operating leverage and gradual margin expansion.

5. New Product Pipeline
Continuous product launches across segments strengthen the portfolio and open up new revenue streams. Over time, this helps in diversifying growth and improving mix.

6. Integrated Ecosystem
Entry into products like dialysis machines creates a razor-blade model, where machine placements drive recurring demand for consumables, increasing customer stickiness and revenue visibility.

Leave a comment

Acquisitions: Expanding Globally

We won’t discuss about this too further now, because of two reasons:

• I have discussed about in previous post in great extent about that.

• The recent acquisitions would consolidate so better to analyze them then.

Share

Valuation Check

The Current PE of the stock is nearly 40 fallen from 100 as I told you earlier!

Still the stock is bit overvalued but also a point to its favor is their strong visibility of growth, according to my estimation company’s 15% growth YoY is very - very conservative to take!

Current EPS at 34.31 (TTM)

So, let’s do a Scenario based:

Base Case

Assumptions

• Earnings growth: 15% CAGR

• Margin expansion: 25% → ~28–29%

• Exit P/E: ~40x (no rerating)

Outcome

• Future EPS: 34.31 × (1.15)^5 = ₹69

• Price after 5 years: 69 × 40 = ₹2,760

CAGR = 15%

Bull Case

Assumptions

• Growth: 20% CAGR

• Margins: reach 30%

• Market perception improves → P/E = 60x

Outcome

• Future EPS: 34.31 × (1.20)^5 = ₹85

• Price: 85 × 60 = ₹5,100

CAGR = 24 - 26%

Bear Case

Assumptions

• Growth slows: 10–12% CAGR

• Margins stuck at 25–26%

• P/E compresses → 35x

Outcome

• Future EPS: 34.31 × (1.11)^5 = ₹58

• Price: 58 × 35 = ₹2,030

CAGR = 5–7% can be negative if situation worsens…

Share Capital Conviction

Summary Insights

Poly Medicure emerges as a structured, execution-driven compounding story, built on the back of a strong consumables-led business model and a clear shift toward higher-value segments. The company benefits from inherently recurring demand, growing export presence, and a gradual move up the value chain into more complex and higher-margin products. Company is also showing great growth numbers in the domestic segment

Management execution has been consistent, with disciplined capital allocation and a long-term strategic approach. However, as the business scales, working capital intensity and capital efficiency become important monitorable. The valuation, already at a premium, leaves limited room for error - meaning future returns will largely mirror execution rather than multiple expansion though it can be you can never judge that.

My Scorecard (SQGLV)

S (Scalability): 8.5/10
Q (Quality): 7.5/10
G (Growth): 8.5/10
L (Longevity): 8.0/10
V (Valuation): 6.5/10

Overall: 7.8/10

Subscribe now

FAQs

Is this a business or a transition story?

A stable consumables business today, but the real upside depends on successfully moving up the value chain.

What if growth remains strong but returns disappoint?

That would indicate valuation compression offsetting earnings growth, which is a key risk in premium stocks.

Is the moat already visible or still forming?

Partly visible in consumables, but the stronger moat is still being built in higher-complexity segments like cardiology.

What can break the thesis without visible revenue decline?

Rising working capital and capital intensity, which can quietly reduce returns even if growth looks healthy.

What would make this a high-return opportunity from here?

Sustained high-teens growth with margin expansion to ~30%, without deterioration in capital efficiency.

Is China dumping a real risk here?

In basic consumables, yes - pricing pressure can emerge. However, as the company moves into regulated, higher-complexity products, this risk reduces significantly. So, you can say it is not into the newer segment, but it is always there in their consumables business though management does very well to cop up with that. That’s for you to study if you wish too.

Disclaimer: Not a buy/sell recommendation. Please do your own research. I am invested so I may have a bias.

Recommend to Others

Standard Disclaimer: This article is for educational purposes only and does not constitute investment advice. Please do your own research or consult a financial advisor before making any investment decisions. Opinions are never fixed and will never be.

I don’t have a long operating history in markets. So, mistakes are expected to happen and it’s part of my journey…

Subscribe now

Topics Covered

• About Poly Medicure

• Acquisitions

About Poly Medicure

Poly Medicure is in the business of selling consumable medical devices. They manufacture the products and sell them in domestic and international markets. The company has expanded itself into 125+ countries. This includes all their acquisitions.

So, let’s understand their main products:

• Infusion Therapy: One which is injecting directly into our blood stream or body directly. For ex. Glucose given to any patient is an example of Infusion therapy, well than injections must be also part of it. So, the answer is no because they are injected only once and not given on continuous basis.

• Renal Care: The dialysis of kidney related consumable products come under this segment. There are various segments in it like but first of all they don’t make dialysis machines. They only make the consumables.

  So, now the sub-segments of Renal Care where Poly Med plays:

1. Bloodlines (Core product)

• Tubes that carry blood from patient → machine → back

• Used in every dialysis session

• High repeat usage → predictable demand

This is one of PolyMed’s strongest categories

2. Dialysis Catheters

• Inserted into veins for access during dialysis

• Includes:

  • Temporary (non-tunneled) catheters

  • Long-term (tunneled) catheters

Moving toward higher-value, specialized SKUs

3. AV Fistula Needles

• Used to access bloodstream during dialysis

• Critical for each session

• Repeat consumption product

  ---

4. Extension Lines & Connectors

• Supporting components in fluid/blood transfer

• Lower ticket but high volume

The Renal segment of Poly Med is currently in India only and contributes roughly 10% of their total revenue and it would take 2-3 yrs to get into other countries for approvals and all.

• Critical Care: Treatment of patients with life-threatening conditions who need constant monitoring and advanced support. The one which are in ICUs. In this, they have a product named IV Cannula as their main product and others are still at very nascent stage so, we can talk about that in detail going further in time may be in 1-2 yrs.

• Orthopedics: It is treatment of bones, joints and muscles etc.

These also mainly includes surgical consumables like IV lines, Catheters after surgery and IV cannula and infusion sets like anesthesia etc. during surgery.

• Cardiology: It is related to treatment of heart and blood vessels.

Earlier, there were only in segment products that we discussed earlier but now there are moving up their value chain, they are moving into stents and ballons.

New Products:

IVL → Intravascular Lithotripsy

DEB → Drug-Eluting Balloon

Dialysis Machines

These all are high value products. They are more complex in nature and demands better margins.

Let’s talk about them in bit of detail:

1. IVL — Intravascular Lithotripsy

Some arteries are hard and calcified (like stone) → normal balloons/stents don’t expand properly.

How it works

1. A special IVL balloon catheter is placed at the blockage

2. Balloon is inflated at low pressure

3. It releases shockwaves inside the artery

4. Shockwaves crack calcium deposits

5. Artery becomes flexible → now stent can expand properly

In short:

IVL = breaks the “stone” inside artery so treatment can work

2. DEB — Drug-Eluting Balloon

After opening an artery, it can narrow again (restenosis).

How it works

1. Balloon coated with medicine (drug)

2. Inserted into narrowed artery

3. Balloon inflated for short time

4. Drug gets absorbed into artery wall

5. Balloon removed

Again, In short:

DEB = opens artery and delivers drug, but leaves nothing behind

3. Renal Machines — Dialysis Machines

Kidneys fail → body cannot:

• Remove waste

• Balance fluids

How it works

1. Blood is taken out via tube

2. Goes into dialyzer (filter)

3. Filter removes waste using semi-permeable membrane

4. Clean blood returns to body

In Short:

Removes toxins and excess water by acting as an artificial kidney.

Acquisitions

Plan1Health: Founded in 1995, headquartered in Amaro, Italy. The business is in oncology segment. They acquired this company in 2018-19 at negative EBITDA. Now at 16-17% EBITDA Margin. The Oncology segment is still not that big and they have not given specific revenue mix of this segment. To give you the rough estimate, it must be around 6-7% of their total revenue.

Citieffe: Founded in 1962, located at Bologna, Italy. The business is in orthopedics segment. Both the Penda Care & Citieffe are recently bought so their full revenue impact will be seen in FY27. So, that is why I won’t comment on these businesses too much for now.

PendraCare: Founded in 2011, Headquartered in Leek, Netherlands. The business is in cardiology segment.

Both recent acquisitions work at around 50-60% current capacity. This will drive cost competitiveness in their domestic (India) segment also.

This is the Part: 1, Part: 2 will come next Tuesday….

This advice is to direct investing investors rather than mutual fund or passive investors.

Before starting, let me clear you one more thing that we are not talking about asset allocation call, or the percentage type of things where you should do 20% debt or something like that stuff in this article. That kind of stuff is very - very individual.

We would be talking about more of general yet successful principles that works really well in market ever since it’s starting.

Capital Allocation: Let’s Build Portfolio

You were you, before anybody told you who you were.

In markets, that line matters more than it sounds.

Because most portfolios are not built from first principles. They are borrowed. Borrowed ideas, borrowed conviction, borrowed timelines from twitter, other social media platforms. And when reality hits, borrowed frameworks don’t hold. Current situation is a good example.

So, striping it down.

This is not about finding the next multi-bagger. This is about building a structure that can survive, adapt and compound.

One more thing, I want to say is that most of the things we will discuss are simple but not easy to do, because when the simple thing appears live, the simplicity of it disappears in our mind.

Starting Where Most People Don’t: Drawdown

Before returns, before sectors, before stock picking - define your drawdown.

Not the one you think you can handle. The one you actually can.

A portfolio that falls 30% behaves very differently from one that falls 15%. Not just mathematically, but psychologically. Decision-making changes. Time horizon shrinks. Conviction disappears. You doubt yourself not just the stock.

Two investors can hold the same stocks. The one whose portfolio is structured within his drawdown tolerance will stay. The other will exit at the worst possible time.

Capital allocation begins here.

If your structure doesn’t match your tolerance, everything else is irrelevant even if that stock becomes a multi-beggar.

This is the issue, are you ready to drop the stock because it is highly volatile and don’t match your drawdown standard. If the answer is no, there is an issue.

Separate Your Portfolio or It Will Confuse You

Most portfolios fail because everything is mixed together. High conviction ideas sit next to experimental bets, and both are given similar importance.

There is a cleaner way to think about this. (This is what I do…)

Break your portfolio into two:

Core portfolio — where your high conviction lies
Satellite portfolio — where your exploration happens with less conviction

The core should contain your most understood businesses. These are the ones where earnings visibility is clearer, downside is relatively limited and your conviction is earned.

Limit this to 10–15 stocks. Beyond that, you’re not allocating - you’re collecting.

The satellite portfolio is different. This is where you take risk. New sectors, early-stage stories, incomplete understanding. But even here, there should be a cap. Not more than 15-20.

The purpose of this is not to generate returns immediately. It is to generate future core ideas. A kind of ideas where one or two accounts for whole returns.

Let Ideas Earn Their Way Up

Most investors make a subtle mistake - they assign conviction upfront.

But conviction is not something you start with. It is something that gets built.

A better way is to let ideas evolve.

Start small. Track execution. Watch management behavior. See how the business reacts under pressure. Let time do its job.

If the thesis strengthens, allocation increases. If it doesn’t, it stays small or exits.

Satellite → Growth → Core

This is the part where you might have completely different view. And I totally respect that view. To take my example, I do the other way around too. I also go fully in one time in some stocks, as the situation changes.

Conviction Density

Two portfolios can look identical on paper and still behave completely differently.

The difference lies in what can be called conviction density.

It’s not about how many stocks you own. It’s about how much weight your best ideas carry.

If your top 3 ideas form 25% of your portfolio, your outcomes will be very different from someone who's top 3 form 50%.

This is where most portfolios quietly underperform.

They are diversified enough to reduce risk but also diversified enough to dilute returns.

The goal is not maximum diversification. The goal is intentional concentration.

Diversification Is Often Misunderstood

Owning 15 stocks does not mean you are diversified.

If 7 of them are driven by the same theme - say premium consumption or export growth - you are effectively making one bet in different forms.

And when that theme slows down, everything slows down together.

True diversification is not across names. It is across drivers.

Different sectors behave differently across cycles. Different earnings engines respond to different macro conditions.

Which is why understanding multiple sectors is not optional.

Subscribe now

Increasing Circle of Competence

If you deeply understand only 1–2 sectors, your portfolio will naturally tilt heavily toward them.

That creates over - concentration risk.

Expanding your understanding to at least 3–5 sectors do two things:

• It reduces forced concentration

• It increases opportunity flow

Markets are cyclical. Opportunities shift. If your understanding is narrow, your portfolio becomes static while the market evolves. If you able to see under-performance for years or so and you are happy with your current knowledge, then no need of expanding your knowledge.

Share Capital Conviction

Know Your Playing Zone

Not every investor is built for every type of stock.

Some businesses require timing (cyclicals). Some require patience (compounders). Some require event tracking (special situations).

If your temperament does not match the nature of the business, you will exit at the wrong time - even if your analysis was correct.

This is very critical to generate good alpha.

Time Horizon Is Not Universal

Two people can buy the same stock and still have completely different experiences.

Because time horizon defines behavior.

If your expectation is 6 months, volatility becomes risk.
If your expectation is 5 years, volatility becomes noise.

There is no correct horizon. Only a suitable one.

Your allocation should reflect that.

Allocation Is Not Static

One of the biggest misconceptions is that allocation is a one-time decision.

It is not. I don’t much of experience in it but that is what my observation is…

As businesses evolve, so should your allocation.

When execution improves and uncertainty reduces, position size can increase.
When valuations stretch or better opportunities emerge, position size should reduce.

Portfolios are not built once. They are continuously shaped.

Rakesh Jhunjhunwala has bought Titan shares at 3 rupees up to even 900 rupees per share. He has bought at 30x price of their first bought price. I mean that’s insane.

Think in Probabilities

Markets reward probabilities, not possibilities.

It is easy to get attracted to outcomes like “this can become 5x.”

But the real question is:
What are the chances it actually will?

A portfolio full of low-probability, high-outcome bets looks exciting but often underdelivers.

A portfolio built on high-probability, reasonable outcomes compounds quietly.

To put it in other way, it is actually margin of safety game. Let’s take an example of portfolio where infra is in core portfolio and constitutes overall 30-35%. Technically, it is very cyclical, very low margin and high capital-intensive business. So, taking this is, it is kind of industry makes sense when you take at steep discounts for their execution parts like just for example at low PE or low PB ratio at beginning of their cycle.

You have to apply the second order thinking and not just the first principles.

Cycles Will Test Your Patience

Every sector has its time.

And more importantly, every sector has long periods where nothing happens.

If you constantly rotate based on recent performance, you end up chasing the past cycle.

In this I would take example of Ramesh Damani where they tell a story here his father gave him $10,000 to invest in US stock market when he was working there. He lost all of his money when there was bull run in the stock market. And what was their mistake, His one of the biggest mistakes in it was looking at past performance of company as an indicator for future outcomes.

Patience here is not inactivity. It is discipline.

Wait for your sectors. Let others run. Your time will also come.

Earnings vs Narrative

In the short term, stocks move on perception.

In the long term, they move on earnings. There is +1 correlation between earnings and stock price of the business.

Portfolios built on perception changes tend to be volatile and inconsistent.
Portfolios built on earnings growth tend to compound.

This doesn’t mean ignoring narratives. It means not depending on them.

Keep It Simple, or You Won’t Follow It

Complex frameworks look good on paper but are hard to execute.

Simple frameworks feel underwhelming but are easier to stick with.

And in investing, consistency beats sophistication.

Share

One more Idea to work with

If everything feels abstract, reduce it to this:

• A core layer that provides stability and compounding

• A growth layer that captures emerging opportunities

• A tactical layer that allows flexibility

Each has a role. Each has a limit. Each behaves differently.

Together, they create balance.

Personally, I don’t really like this one due to various reasons that’s why I kept it at last, but it is also one of idea that exists.

What This All Comes Down To

You don’t really need more ideas or more tips.

You need:

• A structure that matches your psychology

• Allocation that reflects your conviction

• The patience to let both play out (Hardest)

Because at the end of the day:

A good stock in the wrong size does very little.

An average stock in the right size can still move your portfolio.

And a great portfolio is not a collection of stocks.

It is a system of decisions.

Video of the Month

Podcast of the Month

This is from money mindset’s series of Sonia Shenoy with guest Vishal Khandelwal.

The podcast is more philosophical rather than of investing. The learnings would be more for life and of life. So, a good one actually.

Subscribe now

Share Capital Conviction

Leave a comment

Few days ago, I was doing my normal routine work, I saw my sister’s smartwatch near to my desk and it was lying like a scarp, the watch which she loved 2 years ago, my father also bought a smart watch in that same period, now he has shifted to Analog watch.

This paused me for a second and raised a question in me what happened to these smart watches. That’s when I thought to dig down into it. I took help of AI in this for data extraction so though data is mostly verified but keep in mind that bit of numbers may very as there is no real data proofs in some segment.

The topic may not be the most relevant part of our publication, but the lessons are always for everyone.

Learning Objective:

• How people destroy the wrong typos.

• How effective longevity is?

• Trust & Reliability are key factors.

• Innovation is the ultimate need for survival.

• Short term activity can’t beat long term quality.

Starting of War

Smartwatches were thought to be very expensive and luxurious item. The industry was controlled by biggy giants like Apple and Samsung. The cost of each smart watch ranged from 20,000-50,000 rupees. Then, not everyone could afford it.

After COVID 19 situation changed,

• Increased Health Conscious

• Gyms shut → Fitness goes digital

• New smartwatch brands got a niche to play on

Now, Wristwatch not only tells time, but it also counts steps, heartbeat, calories burn, sleep etc.

Now, the pricing war started, and every smartwatch company priced these products at 1,999 or 2,999 rupees unlike west where smartwatches were premium (Apple, Samsung)

Smartwatch market was valued at $0.25 billion in 2019 to $2.5 billion in 2025.

Share Capital Conviction

But how could they afford at this price

The answer to this is China, our low cost, famous cheap quality product manufacturer.

This new age companies plan was simple import the unassembled products, assemble here and package and sell it customer.

In this, still they had 50% gross margin.

Boom & Bust

Owning a smartwatch meant:

I am updating, I am modern, It’s more convenient…

Word of mouth advertising grew faster and faster!

At one time, India became the largest smartwatch market.

Every second person was wearing smartwatch irrespective, he/she was living in tier 1, 2, 3 cities. It was aspiration packaged in plastic and near to fake health checks.

That time companies like Boat, Nosie, Fire Boult, Fastrack exploded.

But the most people were the persons who were first time users who bought it in experiment because it was cheap.

It became common and there was no innovation in it. In name of Innovation, they just launched new designs with same technologies.

What happens when anything becomes common….

It loses its pride. That’s what happened with them.

• Differentiation collapsed (Same UI, Same Sensors)

• Accuracy issues (Chinese product)

And numbers started speaking:

Shipment fell in both the years of FY24 & FY25 by 50% in total from peak of FY23.

Subscribe now

Losing Interest

The first-time buyers just remained the one-time buyer. They had tasted the watches, there was no new invention to try, also people now started understanding that they can’t trust these health trackers. The accuracy of it was very low. You could check heartbeat of vegetables. There were gimmicks in heartbeat monitoring etc.

The usage dropped to Notification only.

Health-conscious or Gym going people preferred premium watches as it was reliable in all tracking arears. Also, once people used the cheap smart watches, they wanted to upgrade to better and premium ones and not to on that again.

The Analog Comeback

While everyone was watching smartwatch numbers….

Analog watches were quietly compounding.

After that much hustle of Smartwatches, Analog still holds 65% of market share.

This is structural demand.

This is a kind of nostalgic watches; you won’t leave it just for trend.

Leave a comment

Why Analog Won Again

Longevity

Analog watches lifecycle is not less than 10 years. Some even works at quality after 20 years. Where Smartwatches tend to be replaced in every 2-3 years.

Collection

You can’t collect many smartwatches; it is not going to sustain for that long. The Analogs in this is one of the most loved collectibles. In an Analog lover house, you won’t see less than 10 watches. This also attaches emotionally to it.

Culture over tech

This is my personal observation that new Gen Zs love more vintage aesthetics than any one-time trendy things except in clothing segment. The minimalist design has been loved more than fancy typos.

Premiumization

Smartwatches under 5000 rupees became so common that it has lost its essence and now there are two types of watches growing one is premium smartwatches which is Apple, Samsung, Garmin etc. and other is one and only Analogs.

Share

So…. Is Smartwatches dead then?

The data shows the collapse; the sentiments suggest fatigue.

But conclusion is misleading, because the volume had slowed but not the revenue or the demand. So, it means premium or the higher value segment is growing at good rate.

It is a transition where under 2000 rupees watches are essentially dead or the market supply is increasing than demand. So, the segment in itself was not sustainable, that is what it had to happen with it. When there is no differentiation, no repeatable demand, no good accuracy; you don’t have stay in market for too long.

Premium Smartwatches segment grew by 147% YoY in FY25.

Conclusion

The Smartwatches grew due to one-time aspiration of people when they saw it cheap, the segment itself grew by more than 500% from FY20 to FY23. When the dust settled, demand slowed, there was no one to do innovation and revive the demand, so it only became a one-time hit. After that people either switched to better premium smart watches or switched back to analog. Analog and premium smart watches remain because of their quality and reliability. The demand of these cheap smart watches could have stayed if the tracking devices had been good if they were more reliable.

Subscribe now

Standard Disclaimer: It is completely from knowledge perspective as I love to explain my thesis and why it fits into my framework...

It is not recommendation as each one has their own risk-taking capability so do your own research too for investment purposes. This should be the base of study and not final answer.

I don’t have a long operating history in markets. So, mistakes are expected to happen and it’s part of my journey…

Subscribe now

Index

1. Industry Outlook

2. Key Metrics to Track

3. Why Dairy Remains Overlooked

4. How it’s changing

5. About Dodla Dairy

6. Business Model

7. SQGLV Framework

8. Concall Analysis

9. Scorecard

10. Key Areas for Further Research

11. FAQs

12. Personal Opinion

Industry Outlook

India is the world’s largest milk producer in world. It constitutes one fourth of total milk production in world. The industry itself contributes approximately 5% to national economy directly or indirectly.

In number terms, it is currently of 21 trillion rupees as of FY25-26 and it is expected to reach 58 trillion rupees growing at 11.7% CAGR till FY34.

Another report suggests the industry growth rate of 12.35% and estimating dairy industry at 57 trillion rupees in FY33.

Overall industry is expected to grow in lower double digits. That’s the conclusion of Outlook.

Key Metrics to Track:

1. VAP % of Sales

2. Milk procurement & Realization

3. Margin Improvement

4. Market Share

Why Dairy Remains Overlooked?

The dairy always gets low PE if we compare it to any other FMCG company because of several reasons:

• Milk is a perishable product that is why you see there are often the regional players than a country widespread business except of Amul.

• They are more cyclical in nature. Any bad flush season can lead to compression in margins.

• The sheer competition from local players and cooperatives tends to always keep in pressure to private players.

• The margins are not scalable in terms of milk (not VAP) as it often acts as a commodity not very different product.

• The other issue is the share of milk as percentage of total dairy products. The value-added products have better margins but the share of it is still small.

How It’s Changing?

Younger generation and even elders one is now increasing their value-added products of milk. This is happening to each and every house knowingly or unknowingly. To give my personal example the curd and paneer consumption has tripled from 2020 even though there are same no. of members of house.

The better example of it would be the Ice-Cream, if we go 5-6 years back, there was very few players in this segment working organized one (or they were very small) but now they account for majority in current even in tier-2 cities.

Amul, the biggest cooperative & organized player in India is 9th largest world’s dairy in the country where out of total 1/4th milk is produced and with being largest consumer, it is not even in top 5 shows the size of opportunity.

About Dodla Dairy

Incorporated in the year 1995, Dodla Dairy Limited is an integrated dairy company based in Telangana. The company derives the majority of its revenue from the sale of milk and dairy based value-added products in the branded consumer market. It also operates in one more business vertical which is their Ografeed named business.

Now, let’s look at 9M FY26 :-

• Milk as % of Sales: 70%

• Curd as % of Sales: 20%

• VAP as % of Sales: 07%

• Bulk as % of Sales: 03%

Business Model

Milk Procurement

The company collects milk directly from thousands of small farmers through village level collection centers (VLCCs).

• Milk tested for fat and SNF quality

• Direct payments to farmers

• Daily procurement ensures consistent supply

Processing & Value Addition

The procured milk is transported to processing plants where it is:

• Pasteurized

• Standardized

• Converted into dairy products

Products include:

• Liquid milk (largest volume)

• VAPs

Distribution

Dodla distributes products through a cold-chain logistics network consisting of:

• Distributors

• Retail stores

• Supermarkets

• Institutional buyers

Because dairy products are perishable, speed and refrigeration infrastructure are critical, creating operational entry barriers.

Revenue Source & Margins

The business earns profit by:

• Procuring milk efficiently

• Processing at scale

• Rest is sold in bulk in lower margins

• Increasing the share of high-margin VAPs

SQGLV Framework

Size:

The company is valued at 6000Cr. Market Cap. with total 224 chilling plants and 18 processing plants. Despite being that small it is in top 5 private players, so there would be value migration for them which benefit the old established brands.

Quality:

• There is great demand stability, milk is essential part of Indian Household.

• They have large farmers network which ensures consistent supply chain.

• Distribution is the king in dairy industry. And they are expanding their distribution reach.

• The biggest weakness in this industry is weak pricing power as milk is still a commodity and people buy cheap if they find high price difference.

• The business operates high working capital efficiency as there is fast inventory turnover.

• The business input cost varies according to procurement & feed inflation.

• They can’t pass price to customer as easily and have to slowly and gradually increase pass on.

Growth Drivers:

Shift to Value-Added Products (VAP)

VAP (curd, paneer, ghee etc.) delivers 2–3× higher margins vs liquid milk.

Organized Market Gaining Share

• India dairy market size: ₹21 lakh crore

• Organized share still only ~40% (rest unorganized)

Rising Milk Consumption

• India is the largest milk producer (~250+ million tonnes annually)

• Per capita consumption growing at ~6% CAGR

Geographic Expansion

• Dodla expanding beyond South India + presence in Africa

• African dairy markets have low per capita consumption vs global avg

• This gives a really huge runway for growth.

Share

Operating Leverage

• Dairy is a high fixed-cost business (plants + logistics)

• As volumes grow, cost per liter declines.

Longevity:

The premiumization in India is a long-term theme, as the brand recall becomes, it tends to create a moat in industry in specific regions. The company then tries to capture more premium segment and people also love to buy better products and services. Whey protein product is one such example in this dairy industry.

Valuation:

PE Ratio: 23. I think it is in range of undervalued to fairly priced range value in my eyes.

CFO/EBITDA: 150%. This is bit increased in this year but in general they trail at 100% to 120% CFO.

Debt to Equity: Company operates on nearly zero debt.

Leave a comment

Concall Analysis

Revenue & Margins

1. Revenue grew 13.75% YoY to 1025Cr Rupees

2. EBITDA margin: 7.7%, PAT margin: 6.7%

• Margins impacted due to:

  • Procurement cost (~₹2.5/liter QoQ)

  • Inability to pass full cost to consumers

Price Hikes

• Current realization: ₹60–61/liter

• Target: ₹63–64/liter (+₹2–3 hike)

• Price hikes are season-dependent (summer season)

Demand & Volume Trends

• Milk volumes grew ~19.6% YoY

• Procurement: 18.3 lakh liters/day (+7.5% YoY)

• Industry faced milk shortage (no flush season)

• Growth constrained by supply, not demand

Value Added Products (VAP)

• VAP mix increased from 23% → 25%

• Long-term target: 30–32% mix

Drivers:

• Curd (core)

• Paneer (emerging)

• Ice cream (seasonal)

Leave a comment

Paneer to Whey Opportunity

• Paneer scaled from 1 ton → 3–4 tons/day

• Required for whey: 10–15 tons/day

Management view:

• Whey is not near-term focus

• It will be explored only after significant paneer scale

Geography Expansion

India (Maharashtra)

• Procurement target: ~5 lakh liters/day

• Potential revenue: ₹500–600 Cr in initial phase

Africa

• Revenue growth: ~34.5% YoY

• Uganda expansion:

  • Capex: ₹50–60 Cr

  • Revenue potential: ₹100 Cr+ initially

  • Margins: ~15% EBITDA

  • Guidance to operationalize by end of FY28.

Procurement & Supply Strategy

• Added ~51 procurement locations

• Focus on self-sufficiency in milk sourcing

• Future growth depends on securing milk, not just selling it.

Industry Reality

• South markets becoming mature (limited growth)

• Growth now driven by:

  • VAPs

  • Geographic expansion (North/West/Africa)

Scorecard

Corporate Governance: 9/10

(I did not see any audit issues or any major or minor red flags. There is skin in the game for promoter, and promoter has stable background history.)

Growth: 8/10

(Increasing VAP sales, Africa expansion etc. we have discussed about it.)

Valuation: 9/10

(Price of it is very juicy, it is trading at low PE without any major concerns in them and industry and company both are growing at good rate.)

Potential Opportunity: 9/10

(The company can expand to whey after may be 5 or 6 years aggressively, the Africa is as I say in 1990s of India so there is huge, untapped region, increase in more products like yogurt in India, new subsidiaries for products under different brand name to cater premium members.)

Key Areas for Further Research

• Capital Allocation efficiency

• Scalability of Africa business

• Analysis of OSAM & Ografeed business

• How strategic development of dairy is taking place

FAQs

Is Dodla a commodity business or a branded play?

Currently closer to a commodity milk business but gradually moving toward a branded VAP-led model. The transition is still in progress.

Can Dodla become an FMCG-like company?

Yes if (but chances are 40-60):

• VAP mix increases to 40%+

• Margins stabilize at 12%+

Why is Africa important?

• Higher margins (~15% vs India ~8–10%)

• Underpenetrated dairy markets

• Long-term growth runway

What can drive stock re-rating?

• Higher VAP mix

• Margin expansion

• Consistent ROCE improvement

Share Capital Conviction

Personal Q&A

• Why am I Investing in commodity business?

If you go deeper, the business is shallow cyclical, the trend of youth population is changing, they are moving towards more premium segment products like yogurt, curd etc.

The other reason of it is in some kind of portfolio construction where I need some long-term stabilizer.

• What’s my expectation from this business?

As I told earlier it is one of the portfolio stabilizers not a multi-beggar theme pick, so in base case I expect around 15-18% CAGR in 5-10 yrs view horizon.

Subscribe now

Disclaimer: This article is for educational purposes only and does not constitute investment advice. Please do your own research or consult a financial advisor before making any investment decisions. Opinions are never fixed.

I don’t recommend anyone any stock as each one has their own risk-taking capability so do your own research too for investment purposes.

I don’t have a long operating history in markets So, mistakes are expected to happen and it’s part of my journey…

Index

1. What is AMC?

2. Revenue stream of AMC?

3. Risks in AMC?

4. AMC Industry Outlook

5. Key Metrics to Track

6. About Canara Robeco AMC

7. SQGLV Framework

8. Management Direction

9. Scorecard

10. FAQs

What is AMC?

AMC stands for Asset Management Company. It is the organisation that invests money on behalf of you and charges some percent of that amount as fee. The organisation has professional persons to manage your money, but all the risks associated with it are always yours.

So, A pool of investors put into a scheme of an AMC, that AMC managers manage all the money and takes their cut and the rest returns are all your profits/loss.

Subscribe now

Revenue Stream of AMC

The AMC earns from the charges they take on AUM which is known as Expense Ratio. This is charged throughout any case irrespective the returns for the customer are positive or negative. The charges on AUM decreases as the AUM of company increases. So, it is a volume game.

Risks in AMC Business

1. Market Dependance:

   If market falls:

   • AUM drops

   • Fees Drops

   • Profit Compresses

2. Performance Risk:

   If fund underperforms:

   • Investors redeem

   • SIP inflow slows

   • Brand Trust Weakens

3. Fund Manager Exit:

   If star fund manager leaves:

   • Investor Confidence Falls

   • AUM Shifts to Competitor

   • New Talent Becomes Risky

4. Regulatory Risk:

   SEBI keeps pushing costs down:

   • Lower margins

   • Profitability shrinkage

Share

Outlook of AMC Industry

The mutual fund industry was on slow growth trajectory from last decade. The real shift in their growth came after covid when people started understanding more about market and campaigns also played a huge role in this.

The second part of story is that currently, mutual funds and equites hold only 6-7% of total household savings of India which is compared to any other developed economy is far-far less. The figure is changing rapidly now, and it may happen that the figures get reversed in next 10 years.

Key Metrics to Track:

AUM: Asset Under Management.

SIP INFLOWS: The SIPs that are coming continuously in fund.

AUM MIX: Different type of assets in AMC.

EXPENSE RATIO: Charges charged or earned by an AMC.

Leave a comment

About Canara Robeco AMC

They are a JV company with a shareholding structure where Canara Bank owns 38% and OCE holds 37%. They were incorporated in 1993 and are the second-oldest asset management company in India. Canara Bank is a scheduled public sector commercial bank, was founded in the year 1906 as a private entity and became a nationalized bank in 1969.

The total MAAUM generated through Canara Bank branches is about 11.00% of its total MAAUM. They also benefit from OCE’s global expertise in investment management, product management, risk management, and other operational departments, which helps us to build strong corporate governance standards, risk mitigation strategy, and diversification of product portfolio.

Framework I use to investigate: SQGLV

Small in Size:

The Company is still valued at 4400Cr. Market Cap with Rs. 1.2 trillion AUM approximately with 55,191 distributors at present. It is ranked currently at 18th position in India and gaining market share in equity segment.

Share Capital Conviction

Quality of Business:

1. The AMC business is cash flow rich business. It works on asset light model with huge operating leverage means to earn next rupee it’s cost decreases and it enjoys benefits of scale.

2. Debt in this type of business is negligible always.

3. ROE & ROCE: The return ratios of AMC is the best across any other AMC. Its ROE is currently at 36% along with ROCE of impressive 47%. Company has maintained that level of returns from past and steadily improving it.

4. One issue with AMCs business is that it is highly regulated one means the SEBI has many restrictions on them. For e.g., the SEBI has proposed to cut down more TER (Total Expense Ratio) of around 5bps on exit loads.

5. So, to better understand this AMC business, it is scaling based business not the margin based if you think.

Growth Drivers:

• Increasing SIP penetration after covid has been insane. Demat accounts in India has become 5x from FY20-FY25. And yet the growth opportunity is hell.

• Financialization of Savings is also very high growing in India.

• Market share of Canara Robeco AMC:

Currently, Canara Robeco AMC is growing along with industry pace, but their internal target of 20% growth is also aligned with it and when mutual fund industry slightly gets slow like in low double digits. It will be more visible that how the AMC plays out.

• B30: Cities beyond top 30 metros of India.

Canara Robeco has the 2nd highest B30 AUM of 24%. The next phase of faster mutual fund growth is expected from second and third tier cities. So, it has already started its presence and opening more and more branches in those cities.

Longevity:

This is low debt, high ROE & ROCE along with rich cash flows so sustainability won’t be an issue until unless they are not able to gain market share or not even grow at industry pace. As Industry itself is expected to grow at 15-18% for next few years.

Subscribe now

Valuation:

EPS GROWTH: Company’s PAT growth is phenomenal with 47% CAGR in 3yrs with sales growth of 35%. In future as company guidance, it should do 20% AUM growth as how industry unfolds.

P/E RATIO: Company trades at 23 PE which to my POV is fairly valued according to their past growth and future industry growth though there are some execution risks involved.

Direction of Management

In AMC business, the direction matters the most as it decides where the niche of an AMC is heading towards. In Canara Robeco, it is currently 90% Equity and 10% Debt, the MD & CEO (Rajnish Narula) joined Canara Robeco in 2007 from approx AUM of 3500Cr. which now has reached to 1.2 lakh Cr. which shows CAGR growth of 21% since his joining.

Even though 21% AUM CAGR sounds good, it actually underperformed top AMCs.

For comparison (approx long-term AUM CAGR from 2007 to 2025):

• HDFC AMC: ~23.5%

• Nippon AMC: ~23%

• ICICI AMC: ~22%

• CRAMC: ~21%

But the bigger issue is market share stagnation:

Equity Market Share still around ~2–3% after decades in mutual fund.

But there is also rational reason behind it, that is it mainly operated in debt related segment till 2020, it was 45% of their AUM. But now they are becoming more and more Equity oriented.

Share

Scorecard

Corporate Governance: 9/10

(This is due to their sticky management as the MD & CEO of company which is Mr. Rajnish Narula has been there in it since 2007)

Growth: 7/10

(It has grown along with industry though not gained any market share, but market grew massively so I kind of can’t distinguish it so well)

Valuation: 9/10

(Price of it is very juicy, it is trading at low PE without any major concerns in them and growing with industry may be market senses their market share stagnation problem which I feel is short term)

Distribution channel: 5/10

(This is their worst performing part their distribution partner has remain weak historically, but they are improving a lot in it now so based on it can go to 6 if they show growth in distribution through AUM through more branches)

Approach: 7/10

(The most important part of it is that Mr. Rajnish Narula has been bit conservative with their strategies may be due to high reputation as they are not even to alternatives like PMS etc. where growth opportunity for them is humongous and ones the other big institutions set up their brand recall, in that case it would become more difficult for them to grow.)

FAQs

If Canara Robeco is one of the oldest AMCs in India, why hasn’t it become one of the largest?

Historically, the AMC operated more like a treasury-focused mutual fund with a large share of debt assets and institutional clients. In contrast, many leading AMCs built strong retail distribution and equity franchises early, which helped them scale faster during India’s equity market expansion.

Does a high equity-oriented AUM mix make the business riskier?

Yes and no.
A high equity mix improves profitability and margins, but it also makes the AMC more sensitive to equity market cycles. During sharp market corrections, equity AUM can fall quickly, which may temporarily impact revenue.

Can bank-sponsored AMCs rely entirely on their parent bank for growth?

Not necessarily. While bank branches provide a large distribution network, Independent financial advisors (IFAs), digital platforms, and wealth managers now play a major role in mutual fund flows. AMCs that build a diversified distribution network tend to grow more sustainably.

Why does market share more important than absolute AUM growth?

In a growing industry, almost all AMCs can grow their AUM. What really signals competitive strength is whether an AMC is gaining market share in equity inflows. Consistent share gains often indicate stronger distribution and brand trust.

This one covered basics of the AMC, the next covers what actually matters more:

If there are any other questions:

You may ask via any of the two options…

• You can directly message me.

• You can comment down below the article.

Leave a comment

Cello World is a leading Indian consumer product company mainly dealing in writing instruments and stationery, molded furniture, consumer housewares, and related products.

I have not spied your house but can surely say you have one or two products that are of Cello, if not you must have used it in your lifetime.

The Rise of Cello Pens

In 1990s to 2000s, Cello became one of the India’s dominant players in market

It built:

• Massive distribution

• Affordable pricing

• Strong brand recall

• Pan India presence

Their Pens name:

Cello Gripper
Cello Butterflow
Cello Maxriter

Subscribe now

The Big Move: Sale to BIC

In 2009, the writing instruments business associated with the Cello brand entered into a deal with French stationery giant BIC.

BIC acquired a majority stake in the Cello writing business.

The logic was simple:

• BIC wanted stronger access to the Indian market.

• Cello had distribution and brand power.

• The deal gave BIC immediate scale.

Change In Path

After the transaction:

• The writing instruments business under BIC operated as BIC Cello.

• Meanwhile, the original promoter group retained control over other Cello businesses like:

  • Plastic household products

  • Insulated ware

  • Steel

  • Opal ware (launched in recent years)

But here’s where it gets dramatic.

Business families don’t always move in one direction forever.

Over time, strategic differences emerged.

Eventually, the partnership between the Cello group and BIC ended.

The Cello group exited the writing instruments business under BIC.

And that’s when something interesting happened.

The Birth of Unomax

After exiting the BIC Cello structure, members of the original promoter family launched a new brand:

Unomax

It wasn’t a small experiment.

Unomax entered the market aggressively:

• Similar price points

• Familiar distribution strategies

• Modern branding

• Gel pen focus

For students, the shift was subtle.

But in industry terms, this was huge.

It meant:

• The original master that built Cello pens was now competing under a new name.

• BIC was running Cello in India.

• And Unomax was challenging from the other side.

A brand war - quiet, but real also quite interesting one.

Result of Unomax

Unomax became a meaningful mid-tier player in India’s pen market — but it never reached the same emotional dominance that early Cello had in the 2000s.

Share

Another Twist in the Tale

In Q3 of FY26 - 27 Cello world recently bought their previous Cello pen brand.

Cello World will now lease and operate that trademark as part of its products.

Not just a licensing tie-up.
Not just a marketing partnership.
A true homecoming of the brand name itself.

This was not just corporate strategy - it was emotional reclamation also.

Now:

• Cello pens will be manufactured and sold under the Cello name by their original family group again.

• The pen coexists with Unomax in the same stable.

• Nostalgia and forward strategy sit side by side.

After nearly two decades, the name that defined a generation’s ink supply is back where it began.

Final Thought

Brands are stories.
And sometimes, stories come back to where they started.

Cello pens may have been sold, divided, split into Unomax and spread across global and local operations - but now it has returned to its original home.

For millions who ever scribbled with one, that feels… poetic.

Don’t go only after the name, read the backstory of it too.

I don’t recommend anyone any stock as each one has their own risk-taking capability so do your own research too for investment purposes.

I don’t have a long operating history in markets So, mistakes are expected to happen and it’s part of my journey…

Outlook Of Hospital Industry

Indian healthcare sector is at fragile state in India, I don’t have to tell the situation of Indian hospitals, govt. spending gives barely any think about it. To tell you the numbers India spends merely 3-4% of overall GDP when compared to 18% in US. But the other part of story is that health insurance demand is growing at more 20% CAGR over last 5 years after Covid. People have become more health conscious than ever. Cherry on top India is in phase of growing income of households after roti, kapda and makan healthcare is next essential to Indian needs. And it is not a short-term trend that can change or get utilized in 4-5 years, it is a long play of decades.

Key Metrics to Track

1. ARPOB: Average revenue per occupied bed.

2. BED CAPACITY: How much bed the hospital have?

3. OCCUPANCY RATE: How much hospital is occupied on average?

4. ALOS: Average length of stay of each person.

About Yatharth Hospital & Trauma Care

Yatharth Hospital is a specialty hospital situated mainly in North - India and to be more specific it is widely spread in Delhi NCR region.

What’s different from its peers is that they are situated only in North - India where they cater to tier 2 and tier 3 cities mainly which also makes me more bullish towards as I think there would be higher growth in lower tier cities.

Also, the company has history of acquiring hospitals and somehow it has become their modus operandi to buy new hospital in every 2-3 years though it’s quite small history, but it should be kept in mind as mgmt. guides to do it in future too.

Leave a comment

Framework I use: SQGLV

Small in Size:

The company is currently valued at 6000Cr. Market Cap with currently only 8 operational hospitals which gives them the long runway of growth with large expansion possibilities.

Quality of Business:

• The hospital business is a capital intensive one which makes mgmt. execution capabilities more important. Besides that, it a high margin business with great scalable opportunities.

• One more important thing is it is cash flow rich business in long term. There is not much of cash flows issues in this industry.

• ROE & ROCE: For now, Yatharth’s ability to generate returns on capital may look bit worse but there is strong reason behind this which is their new acquisitions recently which are running on low occupancy rate but in next 2-3 yrs., they will be back to their original margins if not better

Growth Drivers:

• ARPOB: Currently overall ARPOB it is ~33k. To give you the peers idea their ARPOB is ~60k average (Max, Apollo, Fortis).

  There is big gap due to two reasons:

  1. Lower Tier Cities: They operate in comparatively less per capita income areas, so they are able to charge less than their peers.

  2. New Hospitals: As I told you they have recently acquired many new hospitals so there ARPOB from there is very less.

• BED CAPACITY & OCCUPANCY: Currently the hospital has around 2550 beds with only 67% occupancy rate in overall total, and it plans to do reach 5000 - 6000 beds capacity in next 3-4 years.

• NOIDA INT. AIRPORT: The new airport in Noida will add more foreign patients and will improve their cash flows and help them earn better margins from them.

Tours and travelling are also currently in stress which makes their foreign footprint low in current situation which may last for more sometime. After that, it would be double engine growth from foreign patients.

• GLOBAL EXPANSION: This is not the current business part of company, but they are expanding into Africa though Information centres in Tajikistan, Mauritius, Tanzania and Kenya.

Africa has more untapped market than India itself, it kind of sits at situation of India’s economy of 1980s and 90s so that is thing I would be tracking in company for sure.

Longevity:

Growth alone is not sufficient. It’s not important how longer it grows but it is more important how longer it lasts….

Their longevity depends on:

• New Acquisitions

• Doctor Attrition Rate

• Brand Name

• Customer Trust & Network

Subscribe now

Valuation:

EPS GROWTH: Company’s PAT growth is phenomenal with 43% CAGR in 3yrs with sales growth of 32%. In future as company guidance, it should do easily 20% Sales growth with 25-30% PAT growth in base case.

P/E RATIO: Company trades at 37 PE which to my POV is fairly valued according to their past growth and future plans and their execution capabilities till now.

DEBT/EQUITY: The company has nearly zero debt but there is high chance that the company may increase debt due to capacity expansion plans though they have some cash to pursue that.

CFO/EBITDA: Currently it stands at about 58% where its peer stands at 70% on average. This is mainly due to govt. dependence of them which should be tracked.

FAQs

What risks are there in hospital companies?

Hospital businesses face several operational and regulatory risks, including:

• Government regulation of healthcare pricing

• Dependence on specialist doctors

• High capital requirements for expansion

• Competition from established hospital chains

These factors make execution and reputation particularly important in the healthcare sector.

Metrics to track in hospital companies?

For hospital businesses, a few operating metrics provide important signals about performance:

• Bed capacity growth

• Occupancy rates

• Average revenue per occupied bed (ARPOB)

• Operating margins

• Cash Flows (For Yatharth especially)

These indicators help investors understand whether a hospital chain is successfully scaling its operations.

If there are any other questions:

You may ask via any of the two options…

• You can directly message me.

• You can comment down below the article.

Leave a comment

The Short Version

A Specialized Investment Fund (SIF) is a new SEBI-approved mutual-fund-style product aimed at wealthier or sophisticated investors. It sits between regular mutual funds and high-touch products like PMS/AIFs: more flexibility and strategy choices (long-short equity, debt strategies, sectoral, hybrid, etc.), but with higher minimums and stricter eligibility and disclosure rules.

• Minimum investment: ₹10 lakh (aggregate across strategies at PAN level).

• Only eligible mutual fund houses (AMCs) with required track record/AUM or an experienced CIO can launch SIF strategies.

• SIFs allow strategy flexibility (derivatives, long/short, concentrated bets) but come with high concentration, issuer and risk-management limits.

• Close-ended SIFs have listing and exit rules; open-ended SIFs can permit systematic flows but still target high-ticket investors.

Subscribe now

Why SEBI created SIFs (Why it matters)

Regulators wanted to give retail and HNI investors something between plain-vanilla mutual funds and bespoke, lightly regulated options (PMS, AIFs). The idea: allow AMCs to run strategy-driven products (long-short equity, opportunistic debt, sector rotation, quant strategies) under a mutual fund framework - so you get pooled structure + MF taxation/transparency — but with entry bars so only experienced investors join. This reduces regulatory arbitrage while broadening product choice.

Who can launch an SIF (AMC eligibility)

SEBI sets a bar, so only sufficiently capable AMCs run SIFs.

Typical conditions:

• Either: AMC with ≥ 3 years track record and minimum AUM requirement or an AMC led by a Chief Investment Officer with ≈ 10+ years relevant experience and a minimum AUM under his/her management.

• Trustee board and AMC must satisfy governance, risk-management and compliance capabilities; SEBI needs to sign off on SIF launches.

Investor Eligibility & Criteria

SIFs are not mass-market. Main investor rules:

• Minimum ticket: ₹10,00,000 (₹10 lakh) aggregate across the AMC’s SIF strategies, measured at PAN level. If your total SIF exposure with the AMC falls below this, regulatory actions (like freezes/blocks on debit/redemption) can be triggered until you top it up.

• Target investors: HNIs, family offices, institutional or experienced retail investors who satisfy the monetary threshold.

What strategies are allowed

SIFs were designed to be wide in scope - but with cautions:

• Allowed strategies: Long-short equity, Quant algorithmic, Hybrid equity-debt, Specialized debt segment with credit plays, and others.

• Derivatives: allowed, but SEBI specifies usage boundaries and risk-management processes (varies by strategy; derivatives exposure and margining must be tracked).

• Concentration limits (example): SEBI’s framework provides ceilings on exposure to a single debt issuer by rating band (e.g. AAA issuer limit X% of NAV, AA issuer Y% etc.) and allows AMCs board limited relaxation with justification.

Liquidity & Exit Mechanics

• Open-ended SIFs: can allow subscriptions/redemptions but given the nature of underlying assets (e.g., illiquid credit or concentrated positions), liquidity terms will be stricter (notice periods, gates, exit loads).

• Close-ended SIFs: often required to be listed on an exchange to provide an exit route (SEBI’s push to list close-ended SIFs avoids “locked” investor money).

Fees & Taxation

• Fees: AMCs can charge management fees and performance fees (carry). Performance fees must be transparent and measured on clear high hurdles.

• Taxation: SIFs are structured under the mutual fund framework - tax treatment follows MF rules (capital gains taxation per asset class) rather than AIF/PMS tax treatment.

Risks in SIFs

(Read this first if you plan to invest)

• Strategy risk: long-short and concentrated bets can lose large amounts quickly.

• Liquidity risk: if the SIF holds hard-to-sell securities, redemptions may be delayed or penalized.

• Manager risk: SIF performance hinges heavily on the AMC’s team — track record matters.

• Leverage/derivative risk: magnifies gains and losses, and margin calls can force sales in bad markets.

• Regulatory risk: rules can change; SEBI has already been active in adjusting SIF classifications.

How to evaluate a SIF

Note: The framework can vary for each person....

1. Manager pedigree: 3+ years track record in the specific strategy or CIO with proven experience.

2. Clear strategy doc: Understand the instruments, typical position sizes, stop-loss rules and derivative usage.

3. Liquidity terms: notice period, gates, lock-in, exchange listing (if close-ended).

4. Risk controls: independent risk team, stress tests, limits and audit trail.

5. Fee math: Total expense ratio + performance fee structure and high-water mark mechanics.

6. Tax note: confirm whether the fund’s exposures may trigger unexpected tax treatments.

7. Conflict checks: does the AMC run overlapping strategies that could create conflicts?

8. Regulatory compliance: confirm SEBI sign-off and trustee oversight.

Sources

I used SEBI’s regulatory circular and several major industry explainers and news stories to build this guide - read these to get the source wording and exact clause numbers:

• (Securities and Exchange Board of India)

• (Reuters)

• (Economic Laws Practice)

• (Zerodha Fund House)

Share

Subscribe now

ROE is Return on Equity which means the returns generated by a company on their total equity (reserves + shareholder capital).

ROCE is Return on Capital Employed which means the returns generated by a company with all of their capital employed (equity + debt - excess cash).

So, let’s come back to the main question why BSE’s ROCE > ROE?

This answer lies in their balance sheet:

Did you see that?

• Their Cash Equivalents! (Hint: Excess cash)

• So that means cash equivalents = excess cash!

• Hell no!

• But it very much true-in BSE’s case as they don’t need large cash buffer to operate…

This means that their excess cash would be minused from their Capital Employed but it will be still shown in Shareholders’ Equity!

I hope this helps!

Follow for more such Insights…

I am currently studying in Class 11th, pursuing my studies in Commerce stream!

Now to talk about my Interested fields, I am still a learner in every aspect but love doing research on small caps in private! I love reading books too!

Most favorite part of my life is Finance - Personal, Investing & Wealth Creation!

The world of finance fascinates me - Not just numbers, but the strategies, trends, and innovations that shape economies and people’s lives.

I look forward to sharing my learnings, discussing emerging trends, and gaining perspectives from experienced professionals.

Thank you!!! For your precious time
Have a good day…